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1. INTRODUCTION 
 
Human rotavirus is a leading cause of viral gastroenteritis in infants and children 
worldwide, and it is responsible for 37% of all diarrhea deaths in children under five and 
50-60% of acute gastroenteritis cases of hospitalized children throughout the world (WHO 
2011; Tate and others 2012). WHO estimates that approximately 453 000 children aged 
under 5 years died during 2008 due to rotavirus infection; the vast majority (95%) of these 
children live in developing countries with poor hygienic situations (WHO 2012). On the 
other hand, the deaths from rotavirus infection in developed countries are rare, but it 
remains the one of most common causes of hospitalization for acute gastroenteritis in 
children (Leung and others 2005; Widdowson and others 2005).  
It is generally known that the transmission of rotavirus mainly occurs by faecal-oral routes. 
Humans become infected by person-to-person contact and the inhalation of airborne 
human rotaviruses as well as the ingestion of water or food contaminated with human 
rotaviruses (WHO 2011b). Although the ingestion of drinking water is not the most 
common way of exposure, the presence of human rotaviruses in drinking water poses a 
public health risk due to high morbidity rates at low infectious doses (WHO 2011b). 
Waterborne transmission may be facilitated due to the stability of rotavirus in 
environmental water and its resistance to disinfection treatments (He and others 2009). 
Occasional waterborne outbreaks have been caused by consumption of drinking water 
contaminated with human rotaviruses (Hopkins and others 1984; Villena and others 2003; 
Koroglu and others 2011; Mellou and others 2014).  
Accordingly, the availability of a reliable and reproducible method for detection of 
rotavirus in environmental samples is crucial to identify the infectious risk for public 
health and to reduce their impact on public health (Rosa and Muscillo 2013). However, the 
virological analysis of environmental water samples has been historically challenging 
mainly due to the low concentration of target viruses as well as the presence of inhibitors 
in environmental water (Hamza and others 2011; Rosa and others 2012; Gensberge and 
Kostic 2013). Particularly, the environmental analysis of rotavirus has more difficulties 
and requires different methodological protocols than other enteric viruses (Ruggeri and 
Fiore 2013).  
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Basically cell culture is the gold standard method to examine the infectivity of rotavirus 
(Hamza and others 2011). However, it is not sufficiently sensitive for all rotavirus strains, 
and it is difficult to perform and time consuming (Ruggeri and Fiore 2013). Currently, the 
detection of viral genome using PCR-based molecular assays is the only way to identify 
the infectious risk for the population (Gassilloud and others 2003). Especially, quantitative 
PCR assays (qPCR or RT-qPCR) have become the method of choice for the detection and 
quantitation of health-significance viruses including rotavirus, and this approach is widely 
used in the field of food and environmental virology and continuously evolving (Yeh and 
others 2009; Bosch and others 2011; Rodriguez-Lazaro and others 2012). However, one 
major limitation of using these assays is that they detect and quantify both infectious and 
non-infectious viral genomes, and in consequence they do not provide correct information 
of viral infectivity (Fittipaldi and others 2011). Indeed, numerous studies have showed that 
PCR-based assays resulted in overestimation of viral infectivity (Gassilloud and others 
2003; Duizer and others 2004; Bosch and others 2008, 2011).  
In order to overcome the limitations of current methodologies, some promising methods to 
measure the viral infectivity has been proposed. Among several approaches, pre-treatments 
of viral sample using dyes (EMA and PMA) or enzymes (Proteinase K and RNase) 
combined with qPCR assays would appear to be relatively easy and rapid to perform. In 
addition, the applicability of both pre-treatments to certain human viruses has found to be 
successful in some cases to discriminate infectious and inactivated viruses. However, the 
applicability of such assays to measure the infectivity of rotavirus has not been thoroughly 
investigated yet. 
The present study aimed to develop a reliable and rapid molecular method to quantify the 
infectivity of human rotavirus as health-significance virus in drinking water, and further to 
contribute to the development of molecular methods for correct estimation of infectivity of 
non-cultivable health-significant viruses such as human norovirus.  
In the first part of the thesis, the general aspects of rotavirus and rotavirus disease, the 
significance of rotavirus in drinking water, as well as current and promising methods for 
rotavirus detection in environmental water samples are reviewed. In the second part, the 
potential of using RT-qPCR assay combined with enzymatic treatment or dye treatment to 
assess the infectivity of human rotavirus are investigated and evaluated.   
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2. LITERATURE REVIEW 
2.1 Rotavirus 
2.1.1 Historical background  
 
In 1973, Bishop and colleagues discovered new virus particles in the epithelial cells of 
duodenal mucosa from children with acute gastroenteritis (Bishop and others 1973). The 
viruses with similar morphological appearance had been found in the intestinal epithelium 
of infant mice with diarrhea in 1963 (Adams and others 1963). A year after Bishops’ 
discovery in 1974, Flewett and colleagues named rotavirus after the Latin word rota 
(=wheel) plus virus, since the shape of virus particles  resembled the spokes of wheel under 
electron microscopy as described in Figure 1 (Flewett and others 1974).    
 
Figure 1. Wheel-like shape of rotaviruses under electron microscopy. Adapted from CDC 2011. 
2.1.2 Structure and genome 
 
Rotaviruses are the members of the Reoviridae family (Matthews and Maurin 1979). The 
virion of rotaviruses is characterized as a 70-nm non-enveloped icosahedral particle with a 
capsid (Wilhelmi and others 2003). As shown in Figure 2A, the virion possesses a viral 
genome consisting of 11 segments of double-stranded RNA (dsRNA), and each RNA 
segment encodes one protein, except the segment 11 which encodes two proteins 
(Greenberg and Estes 2009). There are 12 proteins encoded: 6 structural viral proteins 
(VP1, VP2, VP3, VP4, VP6 (VP5+VP6), and VP7) and 6 non-structural proteins (NSP1, 
NSP2, NSP3, NSP4, NSP5 and NSP6), and each of which plays a different role during 
virus life cycle; including cell entry, transcription and replication (Jayaram and others 2004; 
Hu and others 2012).  
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(A)            (B)   
 
Figure 2. Structure and proteins of rotavirus. (A) The viral genome of 11 double-stranded RNA segments is 
analyzed by polyacrylamide gel electrophoresis, and each of 11 gene segments encodes one protein except 
the segment 11, and thus there are 12 proteins encoded: 6 structural viral proteins (VP1, VP2, VP3, VP4, 
VP6 (VP5+VP6), and VP7) and 6 non-structural proteins (NSP1, NSP2, NSP3, NSP4, NSP5 and NSP6). (B) 
The structure of rotavirus virion is determined by image reconstruction after electron cryomicroscopy, and 
viral proteins (VP) construct three concentric protein layers of rotavirus capsid and the capsid of rotavirus is 
structured to protect its genome. Adapted from Greenberg and Estes 2009. 
 
The capsid of rotavirus is structured to protect its genome and deliver it successfully into a 
suitable host cell, in which the genome is replicated and the virus particles make copies 
(Jayaram and others 2004). As depicted in Figure 2B, viral proteins (VP) construct three 
concentric protein layers of rotavirus capsid, and they include an outermost layer, an 
intermediate layer and an inner layer (Jayaram and others 2004). The outermost layers are 
implicated in cell attachment, membrane penetration and cell entry (Patton 2013). They are 
mostly composed of glycoprotein VP7 and the spikes of protease-activated attachment 
protein VP4 (Patton 2013). VP7 is a Ca
2+
 binding protein and a key mediator of Ca
2+
 
driven uncoating of the outermost layer, initiating the replication cycle (Trask and others 
2012). VP4 is susceptible to proteolysis; e.g. trypsin, so that it is cleaved into VP8 and VP5, 
enhancing viral infectivity by several folds and facilitating virus entry into cells (Clark and 
others 1981; Carter and Saunders 2007). The sole component of the intermediate layer is 
VP6, and it surrounds the inner layer (Leung and others 2005). VP6 maintains structural 
integrity during the process of endogenous transcription, and provides mRNA exit 
channels (Jayaram and others 2004). The inner layer of the virion is composed of the core 
shell protein VP2. The viral RNA-dependent RNA-polymerase VP1 and capping enzyme 
VP3 are attached to the inside of the VP2 layer (Patton 2013). Together VP1, VP2 and 
VP3 represent the core of rotavirus virion (Leung and others 2005).  
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The ds RNA genome encodes its own enzymes necessary for transcription and it is capable 
of endogenously transcribing its genome (Jayaram and others 2004). The capped (+) RNA 
transcripts encode the viral proteins and function as templates for the production of (-) 
RNA to make the progeny ds RNA (Jayaram and others 2004). The mode of replication is 
conservative since the ds RNA of the infecting virion remains intact (Carter and others 
2007). Once enough viral proteins have been made in cells, the RNA genome is replicated 
and packaged into newly made double-layer particle in specialized structures called 
viroplasms (Jayaram and others 2004). At the final stage of replication, virus assembly 
takes place by the addition of outer layer of the capsid and the spikes, and then virions are 
released from the cells either by lysis or by exocytosis (Carter and others 2007).  
2.1.3 Classification 
 
Rotaviruses have been classified into five serological groups A to E and two tentative 
groups F and G, mainly on the basis of antigenic specificity of VP6, or more recently 
sequence analysis of VP6 (Kindler and others 2013). Rotaviruses belonging to group A, B 
and C are known to induce infections in both humans and animals, whereas group D, E, F 
and G are only in animals (Matthijnssens and others 2010). Additionally, another group of 
rotaviruses originally named ‘new adult diarrhea viruses or ADRV-N was discovered, and 
recently renamed as group H (Matthijnssens and others 2010; Kindler and others 2013).  
Group A rotaviruses are the leading causes of viral diarrhea, accounting for nearly all 
rotavirus-associated mortality and morbidity, especially in children less than 5 years of age 
(Patton 2013). In consequence, group A rotaviruses have been extensively studied and 
have been classified further using various approaches (Table 1). Currently available 
vaccines are directed against the common group A human rotaviruses (Matthijnssens and 
others 2010; Ghosh and Kobayashi 2011). Group B rotaviruses are genetically and 
antigenicallly distinct from group A rotaviruses, and they causes severe, cholera-like 
diarrhea mostly in adults (Yamamoto and others 2010). They were first identified as adult 
diarrhea rotaviruses (ADRV), which have caused large outbreaks of severe diarrhea 
involving thousands of adults in China (Hoshino and Kapikian 2000). It has been only 
detected in China, India, Bangladesh, and recently in Myanmar (Yamamoto and others 
2010). Group C rotaviruses tend to cause sporadic outbreaks and they have been 
occasionally associated with food-borne contamination (Patton 2013). Group D and E 
rotaviruses are known to infect avian species (Patton 2013). Group F and G rotaviruses 
have been originally identified in chicken in 1984, and have been only found in birds so far 
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(Kindler and others 2013). Group H rotaviruses (also called ADRV-N) have been only 
isolated in a large outbreak among adults in China, with a sporadic case in Bangladesh 
(Matthijnssens and others 2010).  
Table 1. Classification of group A human rotaviruses. Group A rotaviruses have been categorized based on (i) 
whole-genome RNA hybridization patterns (genogroups); (ii) the antigenic properties of VP6, VP7 and VP4 
(subgroups, G-serotypes and P-serotypes, respectively); (iii) the nucleotide sequence analysis of VP7 and 
VP4 (G-genotypes and P-genotypes); and (iv) the migration pattern of the RNA genome segments when 
subjected to polyacrylamide gel electrophoresis (long, short, supershort or atypical electropherotypes). 
Adapted from Maunula 2001. 
 
Classification  Types Based on identification of  
Within Group A   
Genogroup WA-like, DS-1-like, 
 and  AU-1-like  
RNA-RNA hybridization 
Subgroup  I, II Antigenic specificities of VP6  
G-serotypes  
(G:glycoprotein) 
or G-genotypes 
G1, G2…etc 
 
Antigenic properties of VP7  
or sequence analysis of VP7 
P-serotypes  
(P:proteinase) 
P1, P2…etc Antigenic properties of VP4 
P-genotypes P[1], P[2] etc Sequence analysis of VP4 
Electropherotypes long, short, supershort 
or atypical types (e-types) 
Patterns of 11 genes after gel 
electrophoresis of genomic RNA 
 
Recently, a whole genome-based genotyping scheme of group A rotaviruses, also known 
as the Rotavirus Classification Working Group (RCWG) genotyping system has proposed 
(Matthijnssens and others 2008). This RCWG system has recommended to use a uniform 
nomenclature in defining the complete genotype constellation of group A rotaviruses, with 
notation Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx (x representing the genotype number)  
being used to denote the genotype of VP7-VP4-VP6-VP1-VP2-VP3-NSP1-NSP2-NSP3-
NSP4-NSP5 genes respectively (Matthijnssens and others 2011). Until 2011, the whole 
genomes of at least 167 group A human rotaviruses, a limited number of group B and C 
have been analyzed (Ghosh and Kobayashi 2011). In addition, only one complete genome 
sequence exists for group D and two genome sequences are available for group H, but no 
sequence available for group E yet (Ghosh and Kobayashi 2011). Recently, first complete 
genome sequences of group F and G have been described (Kindler and others 2013).  
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2.1.4 Diversity and Evolution  
 
Human rotaviruses display a considerable genetic diversity (Ghosh and Kobayashi 2011). 
Among different groups A, B and C, the sequence identity of 11 gene segments is 
generally less than 60 % (Alam and others 2007; Nagashima and others 2008). The high 
level of genetic diversity within a group and different level of sequence diversity in each 
11 gene segment have been observed (Matthijnssens and others 2008). Moreover, there are 
at least four mechanisms which generate and increase the overall diversity of rotaviruses 
and by which rotaviruses evolve: (i) point mutation or “drift”, (ii) genomic reassortment or 
“shift”, (iii) gene rearrangement, and (iv) interspecies transmission (Iturriza-Gomara and 
others 2001; Matthijnssens and others 2009; Ghosh and Kobayashi 2011).  
The accumulation of point mutations is believed to occur frequently in human rotaviruses 
due to the error-prone nature of viral RNA-dependent polymerase (Matthijnssens and 
others 2009). It results in changes in the gene sequence and thus may affect the function of 
the viral proteins (Ghosh and Kobayashi 2011). Genomic reassortment is an exchange and 
substitution of RNA segments between different rotavirus strains (Ghosh and Kobayashi 
2011). Due to the segmented nature of rotavirus genome, it is a major evolutionary 
mechanism in commonly circulating rotavirus strains (Matthijnssens and others 2009; 
McDonald and others 2009). Most reassortment events across genogroups occurs in the 
genes encoding VP4 and VP7, resulting in the formation of new strains with unusual G/P 
combinations and contributing to overall diversity (Iturriza-Gomara and others 2001; 
Cunliffe and others 2002).  
In addition, gene arrangement within single RNA segment, such as deletions, duplications 
and insertions, causes a change in the size of the RNA segment. However, the overall 
contribution of gene arrangement to the diversity of rotaviruses seems to be lower than 
other mechanisms (Matthijnssens and others 2009). Moreover, the interspecies 
transmission between animal and human rotaviruses is known to be another major 
mechanism generating the diversity of human rotaviruses (Gentsch and others 2005). 
Previous studies have detected several human rotaviruses which have close relations to 
animal strains; for example, feline-like rotaviruses in children in Japan (Nakagomi and 
Nakagomi 1989), porcine serotype G5 rotavirus in Brazilian children (Gouvea and others 
1994), and bovine-like serotype G8 in children in Malawi (Cunliffe and others 2001).  
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2.2 Rotavirus disease 
2.2.1 Burden of rotavirus disease 
 
Nearly all children by 5 years of age have been infected by rotavirus at least once, in both 
developed and developing countries (WHO 2013). It accounts for 37% of all diarrhea 
deaths in children under five and 50-60% of acute gastroenteritis cases of hospitalized 
children throughout the world (WHO 2011; Tate and others 2012). The rotavirus infections 
result in estimated 25 million outpatient visits and 2 million hospitalizations each year 
worldwide (Parashar and others 2003, 2009). WHO estimated that globally around 453 000 
(420 000 - 494 000) child deaths occurred during 2008 due to rotavirus infections, and 
most deaths (95%) occurred in malnourished infants living in socioeconomically 
disadvantaged rural regions in low-income countries, where access to healthcare is poor, 
particularly located in sub-Saharan Africa and Southeast Asia as shown in Figure 3 (WHO 
2012). On the other hand, the deaths from rotavirus infections are rare in developed 
countries, in Australia, East Asia, Europe and North America, but the incidence of disease 
in young children is similar to that of developing countries (Chen and others 2012). 
Soriano-Gabarro and others (2006) estimated that rotavirus accounted for 231 deaths, 
87,000 hospitalizations, almost 700,000 outpatient visits as well as 3.6 million episodes of 
rotavirus disease among the 23.6 million children less than 5 years of age each year from 
2000 to 2003 in the European Union. Thus, in developed countries, rotavirus infection 
remains the one of most common causes of hospitalization for acute gastroenteritis in 
children and leads to major medical costs (Leung and others 2005; Widdowson and other 
2005).  
 
Figure 3. Estimated rotavirus deaths in 2008. National estimates of rotavirus attributable deaths among 
children under five years of age ranged from 98 621 (India) to fewer than 5 deaths (74 countries). Twenty-
two percent of all rotavirus deaths under five years of age occurred in India. Five countries (India, Nigeria, 
the Democratic Republic of the Congo, Ethiopia and Pakistan) accounted for more than half of all rotavirus 
deaths under age five in 2008. Adapted from WHO 2012. 
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2.2.2 Clinical aspects of rotavirus disease 
 
The primary site of rotavirus infection is mature enterocytes of the apical portion of villi in 
the small intestine causing gastroenteritis, and thus the main clinical manifestation is 
diarrhea (Greenberg and Estes 2009; Kindler and others 2013). Multifactorial and 
malabsorptive diarrheas may occur due to the virus-mediated destruction of absorptive 
enterocytes, the virus-induced suppression of absorptive enzymes, and functional changes 
in tight junctions between enterocytes leading to paracellular leakage (Greenberg and Estes 
2009). In addition, the activation of enteric nervous system (ENS) and the effects of 
enterotoxin NSP4 (virus-encoded enterotoxin) seem to mediate secretory components of 
rotavirus diarrhea (Ramig 2004; Greenberg and Estes 2009). However, the mechanism of 
diarrhea induced by rotavirus is not fully understood (Ramig 2004; Greenberg and Estes 
2009). 
However, rotavirus infection is not always limited to the intestine (Greenberg and Estes 
2009). Rotaviruses have been detected in the extra-intestinal sites of the liver, kidney, and 
central nervous system (CNS) (Ramig 2004; Dickey and others 2009; Greenberg and Estes 
2009). Few cases include the finding of virus in the liver following fatal disease (Carlson 
and others 1978), the finding of elevated liver enzymes associated virus infection 
(Kitamoto and others 1993), and the demonstration of viral replication in the liver and 
kidneys of immune-deficient children (Gilger and others 1992). In addition, some clinical 
reports of rotavirus have shown that rotavirus spread and pathogenesis may play a potential 
role to cause viremia (Blutt and others 2003; Lynch and others 2003). 
Rotavirus infections can result in asymptomatic infection, mild diarrhea or severe 
gastroenteritis, after the incubation period of 1 to 3 days (Bernstein 2009; Chen and others 
2012). Rotaviral gastroenteritis is more severe than other causes of gastroenteritis, and it 
often results in dehydration, hospitalization and even death (Bernstein 2009). Although 
rotavirus disease can occur at any age, rotavirus gastroenteritis is most common and severe 
in children 3 to 36 months of age (Dennehy and others 2008; Chen and others 2012). The 
major symptoms in young children include mild-to-severe watery diarrhea, vomiting, and 
low-grade fever, and symptoms usually last for up to 4–8 days (Staat and others 2002; Lee 
and others 2008). Among young children, the first rotavirus infection is most likely to 
produce moderate-to-severe diarrhea disease, but the incidence of moderate-to-severe 
diarrhea decreases with second infections, and third infections are typically asymptomatic 
(Bernstein 2009).  
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Among adults, rotavirus infections have been associated with a wide spectrum of disease 
severity and manifestations; symptoms included diarrhea, fever, headache, malaise, nausea 
or cramping (Anderson and Weber 2004). Particularly, rotavirus infections in adults have 
been often related to epidemic outbreaks (Meurman and others 1977; Foster and others 
1980; Griffin and others 2002) or traveler’s diarrhea (Bolivar and others 1978; Vollet and 
others 1979; Steffen and others 1999). In addition, adults who are in contact with children 
are shown to be at particularly high risk of infection since transmission of rotavirus within 
families from children to parents seems to be a common event (Wenman and others 1979; 
Grimwood and others 1983).   
Treatments primarily aim at symptom relief and the restoration of normal physiological 
functions, as rotavirus disease is usually self-limited (Anderson and Weber 2004). The 
rehydration and maintenance of proper fluid and electrolyte balance remains the mainstay 
of treatment (Leung and Robson 1989). WHO recommends the use of oral rehydration 
formula for children who are mildly to moderately dehydrated, whereas intravenous 
rehydration therapy is recommended for those who have severe diarrhea, intractable 
vomiting or for those too sick to take oral feedings (WHO 2006). In addition, resumption 
of a normal, age-appropriate diet is essential for maintaining the nutritional status of child, 
and it can reduce the morbidity and mortality of rotavirus gastroenteritis (Leung and 
Robson 1989; Nutrition committee 2003). The use of probiotics (Lactobacillus GG, 
Bifidobacterium bifium etc) early in the course of diarrhea is shown to reduce the duration 
of diarrhea and rotavirus shedding in affected patients (Saavedra and others 1994; 
Guandalini and others 2000; van Niel and others 2002).  
In principle, the prevention of rotavirus infection can be achieved by avoiding exposures 
and fecal-oral spread (Anderson and Weber 2004). Contact with sick children and 
potentially contaminated food and water should be avoided, and contaminated objects and 
surfaces should be properly disinfected (Leung and others 2005). General measures such as 
personal hygiene and frequent hand washing may help control outbreaks in hospitals and 
child care center (Leung and others 2005). In addition, breast-feeding is encouraged, as it 
may be associated with milder disease in affected infants (Clemens and others 1993).  
Fortunately, rotavirus infection is regarded as the single most frequent vaccine-preventable 
disease among children, and currently universal rotavirus vaccination is frequently used to 
control the disease (Widdowson and others 2005; Soriano-Gabarro and others 2006). Two 
effective rotavirus vaccines, RotaTeq (Merck) and Rotarix (GlaxoSmithKline) were 
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licensed for use in various countries of the world, beginning in 2004-2005 (Yen and others 
2011). WHO recommends the routine immunization of all infants, and has introduced the 
rotavirus vaccine programs to countries with a high incidence of rotavirus mortality but 
lack of infrastructure or financial resources to develop such programs themselves (WHO 
2009). 
2.2.3 Epidemiological aspects of rotavirus disease 
 
Human rotaviruses are mainly transmitted by faecal-oral route, person-to-person contact 
and the inhalation of airborne human rotaviruses or aerosols containing the viruses (WHO 
2011b). In consequence, they can generate small epidemic outbreaks in all age groups, 
particularly within schools, hospitals, nursing homes, and care centers (Ruggeri and Fiore 
2013). In addition, human rotaviruses are transmitted through faecally contaminated food 
and water, and thus results in occasional waterborne and foodborne outbreaks (WHO 
2011b).  
Earlier study on the seasonality of rotavirus disease found that rotavirus infection was 
certainly more common in the cooler months in temperate regions, whereas seasonal peaks 
of the infections can vary broadly and occur from autumn to spring in warmer tropical 
regions (Cook and others 1990). More recently, however, the seasonality of the rotavirus 
infection is shown to have stronger relation to the level of country development than 
latitude or geographic location (Pitzer and others 2011; Patel and others 2013). Patel and 
others (2013) found that poorer countries, particularly those in Africa, Asia, and South 
America have shown year-round circulation and had lesser seasonal variation in disease 
than more developed countries like Europe, North America and Oceania. In addition, one 
study by Pitzer and others (2011) suggested that the high birth rates and transmission rates 
typical of developing countries may be the reason for the relative lack of rotavirus 
seasonality observed in many tropical countries rather than being driven primarily by 
environmental conditions. 
In accordance with increasing global burden of rotavirus disease and development of 
rotavirus vaccines, the introduction of rotaviruses surveillances program by WHO and 
others helps describing the diversity of rotavirus strains in different countries and their 
regions, and identifying the emerging strains (Chen and others 2012; Patel and others 
2013). Currently, 27 G genotypes and 35 P genotypes have been described, and at least 73 
G/P genotype combinations of group A rotaviruses have been detected (Matthijnssens and 
others 2012; Patton 2013). Globally, G1, G2, G3, G4 and G9 are the most prevalent VP7 
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serotypes; P[4], P[6] and P[8] are the most common prevalent VP4 genotypes (Chen and 
others 2012). Five rotavirus strains of G/P combination; G1P[8], G2P[4], G3P[8] , G4P[8]  
or G9P[8], are the major causes of children rotavirus diseases globally (Patel and others 
2011). Among these strains, G1P[8] rotaviruses are consistently primary cause in North 
America, Austrailia and Europe (70% of infections), whereas less in South America, Asia 
and Africa (20-30%) (Soriano-Gabarro and others 2006; Iturriza-Gomara and others 2009). 
Recently, G12 have emerged and spread globally over the past decade (Matthijnssens and 
others 2009; Patton 2013). 
In developing countries, uncommon G/P combinations may be also a frequent cause of 
disease in young children, and the types of uncommon strains varies from one region to 
another region (Armah and others 2010; Binka and others 2011). WHO surveillance 
program has revealed that predominant uncommon strains are G12P[8], G12P[6] in the 
Southeast Asia, G2P[6], G3P[6] and G1P[6] in the sub-Saharan Africa, G1P[4], G2P[8] in 
the Western Pacific, and G9P[4] in the Americas (WHO 2011a). The chance of rotavirus 
co-infection to generate reassortant viruses seems to be higher in developing countries than 
in developed countries, contributing the greater strain diversity in developing countries 
(Patton 2013). 
2.3 Rotavirus in drinking water 
2.3.1 Waterborne transmission 
 
Human rotaviruses are excreted by patients in large quantities up to 10
11
 particles per gram 
of faeces for periods of about 8 days (WHO 2011b). It means that wastewater receiving 
faecal matter and any environments polluted with human faeces are likely to contain high 
numbers of human rotaviruses (Bosch 1998; WHO 2011b; Rosa and others 2012). A 
significant viral load can be released in effluent discharge and spread to the aquatic 
environment such as estuarine water, seawater and river (Rosa and others 2012). In 
consequence, all types of water including raw or treated sewage, river water, recreational 
water, and drinking water, are potential vehicles of virus transmission as described in 
Figure 4 (Bosch and others 2011). The high stability of rotaviruses in environmental water 
and their resistance to disinfection treatments may facilitate the waterborne transmission of 
rotaviruses (He and others 2009). In addition, rotaviruses are highly contagious and 
infectious dose is very low since as few as 10 particles can cause infection (Chen and 
others 2012). Ultimately, the consumption of contaminated drinking water or fruits and 
vegetables being in contacted with contaminated water poses public health risk, although 
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waterborne transmission of human rotaviruses is a not major route of exposure (Bosch and 
others 1998, 2008, 2011; WHO 2011b). 
 
Figure 4. Possible routes of waterborne transmission of enteric viruses. Viruses are shed in extremely high 
numbers in the faeces and vomit of infected individuals. Pathogenic viruses are routinely introduced into the 
environment through the discharge of treated and untreated wastes. In consequence viral pathogens 
contaminate (a) marine environment, (b) fresh water and (c) ground water. Humans can be exposed to enteric 
viruses through various routes: (d) shellfish grown in polluted waters, (e) contaminated drinking water, (f) 
foods susceptible to be contaminated at the pre-harvest stage such as salad crops, lettuce, green onions and 
other greens; and (g) fruits such as raspberries and strawberries. Adapted from Bosch and others 2008. 
2.3.2 Prevalence of rotavirus contamination in water 
 
Numerous studies have reported the presence of rotaviruses in all types of water including 
wastewater, surface water, and in drinking water as well as in food. The high numbers of 
rotaviruses have been reported in wastewater. In one study in China, He and others (2011) 
screened a total 96 samples of influent and effluent wastewater taken from in three sewage 
treatment systems from November 2006 to October 2007 in order to know the presences of 
enteric viruses. The most frequently detected viruses were rotaviruses (32.3%), followed 
by astroviruses (6.3%) and noroviruses (3.1%). Specifically, rotaviruses were detected in 
44.4% of influent samples, and in 25% of the effluent samples. Similarly, in another study 
in Norway, Myrmel and others (2006) examined the wastewater samples collected from 
the inlet and outlet of three sewage treatment plants, and found that rotaviruses were 
detected in 83%, 72%, and 38% of inlet samples and in 68%, 56%, and 36% of outlet 
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sample in three sewage treatment plants, respectively. In the study conducted in Germany, 
Pusch and others (2005) found that rotaviruses were detected in 3–24% of 123 treated 
wastewater samples collected from three sewage treatment plants. These studies 
demonstrated that untreated and treated wastewater may be a source of viral dissemination, 
and they are responsible for the environmental spread of rotaviruses. 
The presence of rotaviruses has been also reported in surface water and drinking water. In 
one study in China, He and others (2012) collected a total 108 urban surface water samples 
from September 2007 to August 2007, and examined for the presence of enteric viruses. 
Among 63 virus strains identified, the most predominant viruses were rotaviruses (48%), 
followed by astroviruses (5.6%) and noroviruses (4.6%). In another study in Slovenia, 
Steyer and others (2011) screened surface water and drinking water for the presence of 
enteric viruses. Group A rotaviruses were detected in only 17.5% of the total 63 surface 
water samples, while noroviruses were more prevalent (41.3%) in surface water samples. 
On the other hand, among 72 drinking water samples, group A rotaviruses were the most 
prevalent (37.5%), followed by noroviruses (2.8%) and astroviruses (1.4%). These studies 
demonstrated the high prevalence of rotaviruses in surface water and drinking water, and 
highlighted the possibility to get rotavirus infection through the consumption of water.  
Although rotaviruses were estimated to cause only 1% of all food-related illness and death 
(Mead and others 1999), the presence of rotaviruses has been occasionally reported in 
food. In the case of foodborne transmission, the main source of contamination is 
considered to be polluted water that has been in contact with food or inadequately treated 
or untreated sewage used for irrigation (Bosch and others 2008). In one study in Costa 
Rica, Hernandez and others (1997) investigated the presence of rotaviruses in lettuce 
bought in farm markets. Those samples collected during months (from December to 
January) of high incidence of rotavirus diarrhea were positive for rotavirus, and they 
suggested that the lettuce might have been contaminated with sewage. In addition, one 
study in Canada, Mattison and others (2010), they claimed the possible foodborne 
transmission of rotaviruses through the packaged leafy greens, although only 0.4% of 
samples were positive for rotaviruses. In another study in Canada, Brassard and others 
(2012) detected two positive samples of group A rotaviruses in 60 strawberries samples, 
and here irrigation water was suspected to be the source of contamination. These findings 
implied that the possible risk of rotavirus to contaminate food through waterborne 
transmission should be taken into account, even if the prevalence of rotavirus in food is 
expected to be relatively lower than that of other enteric viruses. 
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2.3.3 Waterborne outbreaks 
 
Waterborne rotavirus infections are responsible for significant morbidity and mortality 
(Glass and others 2001; Villena and others 2003; Divizia and others 2004). Occasional 
waterborne outbreaks mainly due to the consumption of drinking water contaminated with 
rotaviruses have been reported (Table 2). Thus, the presence of human rotaviruses in 
drinking water is directly related to public health risk (WHO 2011b).  
Table 2. Rotavirus related waterborne outbreaks due to the consumption of contaminated drinking water. 
 
Month/Year Place/Country Etiological 
agents 
Predominant 
symptoms 
Reference 
March 
2012 
Elassona, Greece 
 
Rotavirus 
 
*AGI; diarrhea, 
abdominal pain, 
vomiting and fever 
Mellou and others 
2014 
November 
2007 
Nokia, Finland 
Norovirus,  
Astrovirus 
Adenovirus, 
Rotavirus, 
Enterovirus 
AGI; diarrhea and 
vomiting 
Maunula and others 
2009 
November 
2005 
Malatya, Turkey Rotavirus  
AGI; diarrhea, 
abdominal pain, fever, 
and vomiting 
Koroglu and others 
2011 
December 
2000 
Tirane, Albania 
Rotavirus, 
Astrovirus, 
Adenovirus, 
Norovirus 
AGI 
Villena and others 
2003 
August 
 2000 
 
Gourdon,France 
 
Rotavirus, 
Norovirus  
Co-infection 
AGI; diarrhea, 
abdominal pain  
and nausea 
Gallay and others 
2006 
April 
1994 
Noormarkku,  
Finland 
Norovirus, small 
round virus, 
Rotavirus  
AGI; abdominal pain, 
severe vomiting, in some 
cases high fever, 
headache and diarrhea. 
Kukkula and others 
1997 
March 
1981 
Eagle-Vail, 
Colorado, USA 
Rotavirus 
AGI; diarrhea and 
vomiting 
Hopkins and others 
1984 
*AGI = acute gastrointestinal illness 
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2.4 Molecular detection of rotavirus in water  
 
2.4.1 Current methods and challenges 
 
Environmental virology research has been focused on aquatic environment including 
wastewater, surface water, and drinking water, mainly owing to public health concerns of 
viral related waterborne diseases and outbreaks (Bosch and others 2008; Gensberge and 
Kostic 2013). Historically, the virological analysis of environmental water samples has 
been challenging due to (i) the low concentration of target viruses; (ii) the presence of PCR 
inhibitors in water; (iii) diverse and evolving nature of viruses (Hamza and others 2011; 
Gensberge and Kostic 2013). Particularly, the environmental analysis of rotavirus has more 
difficulties and requires different methodological protocols than other enteric viruses 
(Ruggeri and Fiore 2013). Thus, there is a need for the reliable and reproducible analytical 
methods for the detection of waterborne viruses such as human rotavirus in environmental 
samples, in order to identify the infectious risk for public health and to reduce their impact 
(Rosa and Muscillo 2013).  
The virological analysis of environmental water is a complex process that can be divided 
into two main steps: virus concentration and virus detection (Bosch and others 2008; 
Hamza and others 2011). As mentioned before, the concentration of viruses in water is 
usually very low, and they are distributed heterogeneously in environmental water samples 
(Rodriguez-Lazaro and others 2012). Thus, a desirable virus concentration method should 
be able to concentrate only viral particles while avoiding co-concentration of inhibitory 
compounds in water samples (Rosa and Muscillo 2013). Currently, three concentration 
techniques are commonly used: adsorption/elution, ultrafiltration, and ultracentrifugation 
(Rosa and Muscillo 2013). After the concentration of target virus from the samples, virus 
detection can be performed with either cell culture which is based on the observation of 
cytopathogenic effects (CPE) caused by viruses to cells, or molecular techniques such as 
PCR or qPCR assays which basically detect the target viral genomes by molecular 
amplification after viral nucleic acid extraction and purification (Bosch and others 2011; 
Rodriguez-Lazaro and others 2012).  
Cell culture 
Cell culture is the standard method to isolate human viruses in environmental samples 
based on the ability of viruses to produce visible cytopathogenic effects (CPE) (Rosa and 
Muscillo 2013). After infectious viruses are propagated in suitable cell culture, the 
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cytopathogenic effects (CPE) can be quantified with plaque assay (plaque forming unit 
PFU) or 50 % tissue culture infections dose (TCID50) (Theron and Cloete 2002; Bosch and 
others 2011). However, the cell culture is basically difficult to perform and time-
consuming, and more importantly, it is not universally applicable to all viruses since some 
viruses are non-cultivable or grown with difficulty (Yeh and others 2009; Rosa and 
Muscillo 2013). In addition, inoculated cell culture often deteriorates before the presence 
of CPE, making it difficult to obtain reliable and reproducible results (Ko and others 2003). 
Nevertheless, to date, it is considered to be the only reliable method to detect and quantify 
infectious viral particles (Yeh and others 2009; Bosch and others 2011).  
Human rotaviruses are difficult to propagate as they are fastidious and may require more 
than 1 week to produce clear CPE (Li and others 2009). Fortunately, several cell lines have 
found to be efficient to some extent, for example, the cell-culture adapted rotavirus strains 
such as the human strain WA (Wyatt and others 1980) or the simian strain SA-11 (Estes 
and others 1979). However, cell culturing is not sufficiently sensitive for all human 
rotavirus strains, especially wild rotaviruses naturally contaminating water (Ruggeri and 
Fiore 2013).  
Molecular techniques  
With the development of molecular biology techniques, the application of PCR-based 
assays which detect the genome of target virus has considerably improved the ability to 
detect viruses in environmental samples (Mackay 2002). In brief, the PCR is a procedure 
by which specific sequence of DNA can be copied and amplified a billion-fold by 
exploiting DNA polymerase and using short sequence-specific primers (Valasek and others 
2005). As PCR assay generally must use DNA as a template and some viral genomes such 
as rotaviruses are solely composed of RNA, reverse transcription-PCR (RT-PCR) assay is 
used (Valasek and others 2005). This assay utilizes reverse transcriptase which generates a 
complementary DNA (cDNA) from a RNA template and then the cDNA can be amplified 
by PCR (Bustin 2000; Valasek and others 2005). The relative amount of a given cDNA 
generated by reverse transcription is proportional to the relative amount of its RNA 
template (Valasek and others 2005). The RT-PCR assay has been applied for rotavirus 
detection in environmental samples in several studies (Gratacap-Cavallier and others 2000; 
He and others 2009; Yang and others 2011a). It has shown to have higher specificity and 
sensitivity for the detection of rotavirus compared to electron microscopy and 
immunoassays (Buesa and others 1996; Tang 2000). On the other hand, conventional PCR 
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assays are time-consuming, labor-intensive and non-quantitative, and they have substantial 
probability of cross-contamination due to post-PCR handling steps (Valasek and others 
2005). 
More recently, real-time quantitative PCR (qPCR) assay has been developed with the 
application of fluorescence techniques to the conventional PCR assay (Bustin 2000). The 
development of quantitative PCR (qPCR) assay has enabled rapid, sensitive and specific 
virus detection as well as quantitation of viral load (Bustin and others 2005; Valasek and 
others 2005). In principle, the qPCR assay integrates both amplification and detection by 
using fluorescent indicators such as double-stranded DNA dyes or fluorescently labelled 
probes, and instrumentations to detect emitted fluorescent signal (Wittwer and Farrar 2011). 
The amount of emitted fluorescence is proportional to the amount of PCR product (Klein 
2002). Since the fluorescence level is detected after each cycle, it is possible to monitor the 
progress of PCR reaction in real-time and measure the quantity of PCR product during 
“exponential phase” in every cycle (Wittwer and Farrar 2011). Thus, the qPCR assay 
enables the accurate estimation of the quantity of initial template (Bustin 2000; Valasek 
and others 2005). Similarly in the RT-PCR assay, reliably generated cDNA from RNA is 
used as the template for qPCR (Valasek and others 2005).  
In addition to the inherent quantitative potential of PCR, the qPCR or RT-qPCR assays 
represent technological advance over conventional PCR assays for several reasons: (i), 
high sensitivity as they have ability to detect less than 5 copies of target sequence and 
quantify the target sequence with a wide dynamic range (7–8 log units) (Klein 2002); (ii) 
minimized cross-contamination as they are performed in a close-tube reaction (Bustin and 
others 2005; Valasek and others 2005); and (iii) rapidness due to reduced cycle time and 
high-throughput automation system (Mackay and others 2002; Valasek and others 2005). 
The RT-qPCR assay has become the method of choice for the detection of RNA viruses, 
and currently, this approach is widely used in the field of food and environmental virology 
and continuously evolving (Yeh and others 2009; Bosch and others 2011; Rodriguez-
Lazaro and others 2012). The RT-qPCR assay has been applied for rotavirus detection in 
environmental water samples in several studies (Verheyen and others 2009; Ganime and 
others 2012; Ye and others 2012).  
However, qPCR or RT-qPCR assays have some limitations in routine virological analysis 
(Bosch and others 2008). The majority of these limitations are also present in conventional 
PCR or RT-PCR assays. First, they are susceptible to obtain either false-positive results 
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due to cross-contamination, or false-negative results due to inefficient nucleic acid 
extraction or due to the presence of inhibitory substance in RT or PCR reaction (Gassilloud 
and others 2003; Yeh and others 2009; Bosch and others 2011). It is generally known that 
RNA is extremely labile compared with DNA, and therefore isolation must be carefully 
performed to ensure both the integrity of the RNA itself and the removal of contaminating 
nucleases, genomic DNA, and RT or PCR inhibitors (Valasek and others 2005). In addition, 
quality control (QC) measures by using positive and negative controls are critical (Bosch 
and others 2011; Rodriguez-Lazaro and others 2012). Moreover, a careful selection for 
highly conserved sequences targeting primers and probes is required for effective detection 
and absolute quantification in spite of the genomic diversity of viruses and continuous 
emergence of new virus variants (Bosch and others 2008). 
In addition, it is critical to know the information on the number of viral particles with 
infective capacity in the field of environmental virology (Rodriguez-Lazaro and others 
2012). However, the detection of the viral genome by itself does not provide any 
information about the infectious nature of the viruses (Duizer and others 2004; Bosch and 
others 2008; Yeh and others 2009). In consequence, the PCR-based molecular methods 
often lead to false-positive results and overestimation of viral infectivity (Gassilloud and 
others 2003; Duizer and others 2004). Duizer and others (2004) found that for most 
disinfection methods applied at levels where viral infectivity could no longer detected, 
viral RNA remained detectable by PCR assay. They demonstrated that the detection of 
viral RNA using PCR-based assays underestimated the reduction in viral infectivity. Choi 
and Jian (2005) also observed the discrepancy between the high number of genome copies 
of viruses detected by RT-qPCR and absence of infectivity detected by cell culture. They 
suggested that PCR results significantly overestimated the occurrence of infectious viruses 
in environment. These studies demonstrated that positive PCR results do not allow a 
definitive evaluation of the infectious capability of the viral genomes detected, although 
negative PCR results obtained with well standardized quality controls and highly sensitive 
PCR assays can provide robust evidence for the absence of pathogens or indicators in the 
samples (Rodriguez-Lazaro and others 2012).  
Overall, the detection of viral genomes, especially for non-cultivable viruses, may be 
necessary to identify infectious risk for the human population but it is not sufficient for 
assessment of infectious risk (Glassilloud and others 2003). Thus, utmost caution should be 
taken in directly extrapolating positive PCR results of human viruses to assess public 
health risks (Choi and Jiang 2005).  
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2.4.2 Promising methods to measure viral infectivity by PCR-based assays 
 
Viral infectivity can be defined as the capacity of viruses to enter the host cell and use the 
cell resource to replicate and produce infectious viral particles, which may lead to infection 
and subsequent disease in the human host (Black 1996; Rodriguez and others 2009; 
Rodriguez-Lazaro and others 2012). For viral infectivity, the functional integrity of two 
components; viral capsid and viral genome, is required (Strauss and Strauss 2002; 
Rodriguez and others 2009). An undamaged viral capsid is critical for the initiation of a 
successful infection, while at the same time the replication and translation of the viral 
genome to viral proteins and enzymes are important for the successful production of new 
viral particles (Rodriguez and others 2009). PCR-based molecular assays have been used to 
determine the presence of amplifiable undamaged genome which may indicate the good 
condition of viral capsid protecting viral genome (Rodriguez and others 2009). However, 
current limitations of using PCR based assays to determine viral infectivity have led to the 
recent development of the PCR assays combined with other techniques such as (i) pre-
sample treatments with dyes or enzymes, (ii) immunocapture of the virus from the sample, 
(iii) cell culture and (iv) oxidative stress marker. 
Dye treatment prior to PCR-based assays (EMA- or PMA-PCR) 
 
One of the promising approaches to measure viral infectivity is pre-treatment of viral 
sample with a viability dye, such as ethidium monoazide (EMA) or propidium monoazide 
(PMA), prior to PCR assay (Fittipaldi and others 2011). EMA is a photosensitive analog of 
ethidium bromide (EB) which has been used as a DNA intercalating agent (Yielding and 
others 1984). PMA is identical to propidium iodide (PI) except the presence of an 
additional azide group allowing cross-linkage to DNA upon light exposure (Nocker and 
others 2006). In theory, both dyes can ideally only penetrate membrane-compromised dead 
cells and suppress its amplification, but not intact cells (Fittipaldi and others 2012). The 
mechanism of amplification signal suppression is not fully understood (Fittipaldi and 
others 2012). One possible mechanism was suggested that the azide groups that both dyes 
have in common, may be converted into highly reactive nitrene radicals and they allow 
covalent cross-linkage to DNA upon light exposure (Fittipaldi and others 2012). Such a 
binding event is assumed to modify DNA and inhibit its amplification by PCR (Nocker and 
others 2006). On the other hand, the excess dyes may react with water molecules and may 
be converted into hydroxylamine, and in consequence they may be no longer reactive 
(Nocker and others 2008).  
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The concept of EMA-PCR assay was first introduced by Nogva and others (2003) to 
differentiate viable and dead cells in bacterial culture. The EMA-PCR assays were shown 
to selectively amplify and quantify target DNA of viable cells of bacteria in some studies 
(Rudi and others 2005; Wang and Levin 2006). However, EMA has shown to also 
penetrate to viable cells of some bacterial species in other studies (Nocker and Camper 
2006; Kobayashi and others 2009). Few studies have applied the EMA-PCR assays on 
enteric viruses, and the effect of EMA treatment has shown to be different depending on 
the virus species: Graiver and others (2010) found the ineffective binding of EMA to avian 
influenza viral genome, while Kim and others (2011) claimed the potential of using EMA 
treatment for selective detection of polioviruses. The lack of specificity for intact cells or 
capsid has remained the greatest concern with the application of EMA treatment (Fittipaldi 
and others 2012). 
As the alternative molecules of EMA, PMA was invented later by Nocker and others 
(2006), and the higher impermeability of PMA than EMA through intact cells of bacteria 
was shown in their study. Since their invention, the PMA-PCR assays have been 
successfully applied in a wide range of microorganisms including bacteria (Yang and 
others 2012; Kaushik and others 2013; Zhang and others 2013), bacterial spores 
(Mohapatra and others 2012), fungi (Vesper and others 2008), and yeast (Andorra and 
others 2010). More recently, few studies have employed the PMA-PCR assays to different 
types of viruses (Table 3).  
PMA-PCR assay is considered to be a promising tool as it is easy and rapid to perform and 
it can provide viability information (Fittipaldi and others 2012). In addition, it can 
potentially applicable to non-cultivable viruses to examine viral infectivity (Hamza and 
others 2011). On the other hand, the generation of false-positive signals due to incomplete 
signal suppression remains to be the greatest concern with the application of PMA 
treatment (Fittipaldi and others 2012). For further evaluation of this assay, see the 
discussion section.  
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Table 3. Overview of the publications where PCR-based assays combined with PMA pre-treatment were 
employed to discriminate between infectious and inactivated viruses. 
 
Detection 
method 
Viruses Inactivation method Reference 
PMA-RT-qPCR  Bacteriophage T4 Heating at 85 °C or 110 °C, 
Proteolysis 
Fittipaldi and others 2010 
PMA-RT-qPCR  Coxsackievirus, 
Poliovirus, Echovirus,  
Norwalk virus 
Heating at 19 °C, 37 °C,  
or 72 °C,  
Hypochlorite. 
Parshionikar  
and others 2010 
PMA-RT-qPCR  Bacteriophage MS2, 
Murine norovirus 
Heating at 72 °C or 80 °C Kim and others 2012 
PMA-RT-qPCR  Hepatitis A virus Hypochlorite,  
High-pressure,  
Heating at 99 °C 
Sanchez and others 2012 
PMA&surfactants 
- RT-qPCR  
Hepatitis A virus, 
Simian rotavirus, 
Human rotavirus 
Heating 37 °C, 68°C, 72°C or 
80 °C 
Coudray-Meunier  
and others 2013 
Enzymatic treatment prior to PCR-based assays 
 
Another promising approach to assess viral infectivity is enzymatic pre-treatment of viral 
sample prior to PCR assays (Nuanualsuwan and Cliver 2002). This approach is based on 
the ability of viral capsid to protect the genomes from protease and nuclease. In principle, 
viral capsids of infectious viruses must be sufficiently intact to protect the viral genome 
from degradation. Nuanualsuwan and Cliver first proposed the pre-treatment of viral 
sample with both proteinase K and RNase prior to PCR to discriminate between infectious 
and inactivated viruses. They hypothesized that viral capsids of inactivated viruses can be 
more easily degraded by enzyme such as protease. Then the degraded capsids may allow 
unprotected nucleic acid to be exposed and degraded by nuclease, yielding a negative PCR 
result. On the other hand, intact capsids may protect nucleic acid from protease and 
nuclease, resulting in a positive PCR result. Later, this approach has been applied to 
different types of viruses (Table 4). Similarly as dye treatment, enzymatic treatment is easy 
and rapid to perform, and it can be potentially applicable to non-cultivable viruses to assess 
the viral infectivity (Hamza and others 2011). However, the capsid integrity alone as the 
criterion for viral infectivity may be limited (Pecson and others 2009; Hamza and others 
2011). For further evaluation of this assay, see the discussion section. 
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Table 4. Overview of the publications where PCR-based assays combined with enzymatic pre-treatment 
were used to discriminate between infectious and inactivated viruses. 
 
Detection 
method 
Viruses Inactivation method Reference 
Proteinase K and 
RNase-RT-PCR  
Hepatitis A virus,  
Poliovirus, 
Feline Calicivirus  
Ultraviolet light, 
Hypochlorite,  
Heating at 72 °C. 
Nuanualsuwan  
and Cliver 2002 
Proteinase K and 
RNase-RT-PCR 
Human Picornavirus, 
Feline Calicivirus 
Ultraviolet light,  
Hypochlorite,  
Heating at 37 °C, 72 °C 
Nuanualsuwan  
and Cliver 2003 
Proteinase K and 
RNase-RT-q PCR  
Murine norovirus Heating at 80 °C Baert and others 2008 
RNase-RT-q PCR  Feline Calicivirus,  
Human norovirus 
Heating at 20 – 80 °C  Topping and others 2009 
Proteinase K and 
RNase-RT-q PCR  
Bacteriophage MS2 Ultraviolet light,  
Singlet oxygen,  
Heating at 72 °C 
Pecson and others 2009 
RNase-RT-q PCR  Hepatitis A virus Hypochlorite,  
High-pressure,  
Heating at 99 °C 
Sanchez and others 2012 
Pronase and 
RNase-RT-q PCR  
Human norovirus,  
Murine norovirus 
Ultraviolet light Rönnqvist and others 
2014 
 
Immunomagnetic separation prior to PCR-based assays (IMS-PCR) 
 
Immunomagnetic separation technique utilizes paramagnetic beads coupled to a virus-
specific antibody targeting viral antigen, allowing the separation of virus from 
contaminating materials and virus concentration in a single step (Gilpatrick and others 
2000). The combination of immunomagnetic separation method and PCR assays (IMS-
PCR) was first developed by Grinde and others (1995) for rotavirus detection. They found 
that this assay provided a better correlation with viral infectivity than either method alone. 
This assay enabled the detection of target viral genome packed in capsid proteins, not just 
the presence of proteins or of naked viral genome (Grinde and others 1995). Later, this 
method has been applied for the detection of enteric viruses such as enterovirus (Casas and 
Sunen 2002), hepatitis A virus (Casas and Sunen 2002), human norovirus (Gilpatrick and 
others 2000; Myrmel and others 2000), human rotavirus (Grinde and others 1995), and 
simian rotavirus (Casas and Sunen 2002; Yang and others 2011b). 
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Casas and Sunen (2002) suggested that this method was relatively rapid and easy to 
perform and it enabled efficient, sensitive and specific detections of enteric viruses in 
environmental samples despite the presence of complex inhibitory substances. In addition, 
Yang (2011b) found that this assay had higher virus recovery efficiency by removing the 
PCR inhibitors in complex sewage concentrates, and the results showed a good correlation 
with cell culture. On the other hand, this method seems to be highly dependent on 
antigenic properties of the viral capsids, so that the conformational changes in the viral 
proteins could inhibit the interaction with antibodies (Rodriguez and others 2009). In 
addition, it may require a specific assay for each virus strain since certain antibody may not 
able to target all possible strains of the viruses (Hamza and others 2011).  
Integrated cell culture-PCR-based assays (ICC-PCR) 
 
Integrated cell culture with PCR (ICC-PCR) is an approach to overcome most of the 
disadvantages of both cell culture assay and PCR assay (Rodriguez and others 2009). 
Detection is based on an initial biological amplification of viral nucleic acid using cell 
culture and followed by PCR amplification (Hamza and others 2011). In consequence, it 
enables the selective enumeration of infectious virus with rapid detection (Rigotto and 
others 2010). Reynolds and others (1996) first introduced the ICC-PCR assay for detection 
of human enteric viruses in environmental samples. Since then, the ICC-PCR assays have 
been applied for the detection of human enteric viruses including adenovirus (Greening 
and others 2002; Cheong and others 2009; Amdiouni and others 2011), enterovirus 
(Reynolds and others 2001; Greening and others 2002; Shieh and others 2008), hepatitis A 
virus (Reynolds and others 2001), poliovirus (Blackmer and others 2000), human rotavirus 
(Rutjes and others 2009; Li and others 2009, 2010, 2011), and simian rotavirus (Li and 
others 2009, 2010, 2011) in environmental water samples. 
Reynolds and others (2001) found that ICC-PCR was useful for the evaluation of viral 
infectivity in accordance with cell culture assay with shorter incubation time. In addition, 
Li and others (2009) showed that ICC-RT-qPCR was more effective, sensitive and faster 
than direct RT-PCR for rotavirus detection with the information of infectivity. Moreover, a 
cell culture step may eliminate or reduce inhibitory compounds in environmental samples 
(Rodriguez and others 2009; Gensberger and Kostic 2013). However, it may require 
multiple cell lines and it is not applicable for non-cultivable viruses, such as human 
norovirus (Hamza and others 2011). 
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Oxidative stress marker 
 
A novel approach to assess the infectivity of non-cultivable viruses was recently proposed 
by Sano and others (2010). In theory, some amino acids such as lysine, arginine, proline, 
and threonine can form carbonyl groups by the oxidative reaction with different chemicals, 
and then this carbonylation on protein molecules could result in the loss of protein 
functions (Levine 2002; Temple and others 2006). Non-enveloped enteric viruses could be 
injured by exogenous stress in natural environment, and damages on viral capsid would 
lead to loss of infectivity (Sano and others 2010). Accordingly, cumulative carbonyl 
groups on viral particles created by oxidative stress may be detected by labeling with a 
biotin that can bind to the carbonyl group, and then damaged virus particles (biotinylated) 
could be separated from intact virions (non-biotinylated) using avidin-immobilized affinity 
chromatography (Mirzaei and Regneler 2005; Tojo and others 2013). Thus intact and 
damaged virions can be separately quantified by PCR assays (Tojo and others 2013). This 
approach has been only applied to the detection of human astrovirus and norovirus (Sano 
and others 2010) and rhesus rotavirus (Tojo and others 2013).  
Sano (2010) claimed that the oxidative products on viral capsid proteins might be 
quantitatively detected as an indication of viral particle integrity, which has a significant 
correlation with viral infectivity, and thus the direct detection of oxidative damage by this 
approach seemed to be a powerful tool for the evaluation of viral infectivity of non-
cultivable viruses. Later study by Tojo (2013) confirmed the ability to determine the 
reduction level of viral infectivity using this method, and the infectivity reduction level 
was equivalent to that achieved using the plaque assay. However, the absence of oxidative 
damage may not ensure that viruses are still infectious, in case other mechanisms have led 
to virus inactivation in the environment, and furthermore it may not be applicable in 
routine basis due to the high cost (Hamza and others 2011). 
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3. EXPERIMENTAL RESEARCH 
3.1 Aims of the present study 
 
The aim of the study was to develop a reliable molecular method for rotavirus detection 
with information on viral infectivity, and which may also contribute to the development of 
molecular detection methods for non-cultivable health-significant viruses such as human 
norovirus. The specific aim was to evaluate the potential of using RT-qPCR assay 
combined with PMA or RNase treatment to assess the infectivity of human rotavirus 
(HRV), in comparison with using RT-qPCR assay without any pre-treatment. The cell 
culture-based infectivity assay was used as a reference method to measure the infectivity of 
HRV. It was hypothesized that using RT-qPCR assay with pre-treatments would be able to 
selectively distinguish between infectious and thermally-treated HRV.  
3.2 Materials and methods  
3.2.1 Virus and host cell 
 
MA-104 African green monkey epithelial cell line (ATCC
®
 CRL-2378.1) was obtained 
from Professor Lennart Svensson at the Linköping University (Linköping, Sweden). MA-
104 cells were grown in Eagle’s Minimum Essential Medium (EMEM) (Sigma-Aldrich 
Co. Saint Louis, MO, USA), containing 10 % heat-inactivated foetal bovine serums (FBS) 
(Thermo Fisher Scientific Inc. Waltham, MA, USA), 10 mM HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) solution (Sigma-Aldrich Co.) and 1 % glutamine-
penicillin streptomycin (Sigma-Aldrich Co.). The cells were grown at 37 °C in an 
atmosphere containing 5 % CO2. Cells from passage 5 to passage 35 were used for the 
experiments.   
Human Rotavirus (HRV) WA strain G1P[8] was obtained from Professor Lennart 
Svensson at the Linköping University (Linköping, Sweden), and was propagated in MA-
104 cells. To produce virus stock, HRV WA strain was cultivated on confluent (80 %) cell 
monolayer for 2 – 3 days, and after appearance of the cytopathogenic effect (CPE) using a 
light microscope, the infected cells were frozen and thawed three times and then 
centrifuged at 4.5 x 10
3
 g for 10 minutes at 4 °C to remove residual debris. The supernatant 
was subjected to ultrafiltration (Amicon Ultra-15; Millipore, Billerica, MA, USA)  at 4.5 x 
10
3
 g for 10 minutes at 4 °C and the supernatant from the ultrafiltration unit was recovered, 
and adjusted to 2 ml with 1 x PBS, and stored in aliquots at – 70 °C.  
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The original HRV stock (containing 3.29 x 10
5
 TCID50/ml) produced as above was used in 
cell culture-based infectivity assay. Two different conditions of the HRV stocks were 
prepared for RT-qPCR assay as following; HRV stock A (concentration of 3.29 x 10
3
 
TCID50/ml) which was diluted to 10
-2
 of the original virus stock due to the much higher 
sensitivity of RT-qPCR assay than cell culture-based infectivity assay; and HRV stock B 
(concentration not measured) which was diluted 10
-2
 of the original virus stock and 
subjected to RNase treatment (described in detail in section 3.2.6) in order to remove the 
possible presence of external RNA. Figure 5 describes the flow chart of experiments.  
 
 
Figure 5. Flow chart of the experimental protocols; (1) original HRV stock (containing 3.29 x 10
5
 
TCID50/ml) was thermally treated at 80 °C for different time points, and the infectivity was measured by cell 
culture-based infectivity assay, (2) HRV stock A (containing 3.29 x 10
3
 TCID50/ml) was thermally treated at 
80 °C for different time points, and the virus titer was measured by RT-qPCR assay, RT-qPCR assay with 
PMA or RNase treatment, and (3) HRV stock B was thermally treated at 80 °C for different time points, and 
the virus titer was measured by RT-qPCR assay, RT-qPCR assay with PMA or RNase treatment. 
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3.2.2 Infectivity assay  
 
The infectivity of original HRV stock was measured by determining the 50 % tissue 
culture infectious dose (TCID50). In brief, MA 104 cells were diluted in EMEM containing 
10 % FBS to a concentration of 1.0 x 10
6
 cells/ml, and 500 µl of cell suspension was 
seeded into each well in a 24-well plate. After 24 h of incubation at 37 °C under 5 % CO2, 
each well was washed with PBS once, and EMEM containing 0 % FBS was added. After 
24 h of incubation, 200 µl of each 10-fold serial dilution of trypsin-activated HRV were 
added to four parallel wells on the plate per dilution. The plates were incubated at 37 °C 
under 5 % CO2 and checked daily for the presence of CPE using a light microscope. The 
wells with CPE were recorded as positive. The final recording was performed after 7 days 
and TCID50/ml was calculated using by Spearman and Kärber formula as described in 
Hierholzer and Killington (1996).  
3.2.3 PMA treatment  
 
PMA (propidium monoazide) was purchased from Biotium, Hayward, CA, USA at 20 mM 
in H2O and diluted in sterile H2O to obtain the solutions used in this study. The PMA 
solution was stored at – 20 °C in the dark. PMA was added to aliquots of 140 µl of HRV 
stock A or B to chosen concentrations, and incubated for 5 min in the dark at room 
temperature prior to light exposure for 15 min using the PMA-Lite LED (Light-emitting 
diode) Photolysis Device (Biotium, Hayward, CA, USA). 
Prior to the optimal concentration (100 µM) of PMA being chosen for further studies, the 
effects of light exposure and different concentrations (50 and 100 µM) of PMA on 
infectious HRV stock A (3.29 x 10
3
 TCID50/ml) were preliminarily tested. Two different 
final concentrations of PMA were added to infectious HRV stock A. HRV stock A without 
PMA treatment was used as a control. Two identical sets of samples were prepared: one set 
of samples was exposed to light and the other set was not.  
3.2.4 PMA treatment of viral RNA 
 
The binding of PMA to viral RNA was tested to check whether the final concentration of 
100 µM was sufficient enough to bind viral RNA and inhibit its amplification by RT-q 
assay. In detail, viral RNA was extracted from six aliquots of 140 µl of HRV stock A and 
eluted in 60 µl of elution buffer, according to the manufacturer’s instructions with QIAmp 
Viral RNA Mini Kit (QIAGEN, Hilden, Germany).  The eluted viral RNAs were pooled to 
obtain homogeneous RNA stock. First, three different viral RNA samples were prepared as 
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following: one sample without any treatment, another one treated with PMA at a final 
concentration of 100 µM followed by light exposure, and the other treated with PMA at a 
final concentration of 100 µM followed by no light exposure. In addition, in order to 
remove the potential inhibitory effect of unbound PMA to RT-qPCR assay, identical 
samples were prepared as above, but then the samples were purified by using QIAquick 
PCR purification kit according to manufacturer’s instructions. Finally, all samples were 
analyzed with RT-qPCR assay.   
3.2.5 RNase treatment  
 
RNase was purchased from Roche Diagnostics, Indianapolis, IN, USA and diluted in 
sterile Tris-HCI, H2O and glyserol to obtain the solutions used in this study. The RNase 
solution was stored at – 20 °C. The chosen doses of RNase were added to aliquots of 140 
µl of HRV stock A and B, and incubated at 37 °C for 30 min, after which 80 U of RNase 
inhibitor (RiboLock, Thermo Fisher Scientific Inc, Waltham, MA, USA) was added. 
Prior to the optimal dose (0.08 mg) of RNase being chosen for further studies, the effects 
of different doses (0.04 and 0.08 mg) of RNase on infectious HRV stock A (3.29 x 10
3
 
TCID50/ml) was preliminarily tested. Two different doses of RNase were added to the 
HRV stock A. HRV stock A without RNase treatment was used as a control.  
3.2.6 Heat treatment  
 
Heat treatment was conducted to study the potential of using PMA or RNase treatment to 
discriminate between infectious and thermally-treated HRV. In the preliminary tests, heat 
treatment at 37, 80, and 97 °C was selected to monitor the potential of both pre-treatments. 
HRV stock A (3.29 x 10
3
 TCID50/ml) was incubated for 30 min at each temperature using 
a dry bath set. For PMA experiment, the effects of different concentrations (50 and 100 
µM) of PMA on thermally-treated HRV stock A were tested. Two different final 
concentrations of PMA were added to thermally-treated HRV stock A. The HRV stock A 
without PMA treatment was used as a control. For RNase experiment, the effects of 
different doses (0.04 and 0.08 mg) of RNase on thermally-treated HRV stock A were 
tested. Two different doses of RNase were added to thermally-treated HRV stock A. The 
HRV stock A without RNase treatment was used as a control.  
Heat treatment at 80 °C was chosen for further studies. First, the original HRV stock (3.29 
x 10
5
 TCID50/ml) was thermally treated by using a dry bath set at 80 °C for 0, 1, 5, 10, 20, 
30, and 60 min, after which the samples were immediately placed on ice. The infectivity of 
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the thermally-treated HRV stocks at different time points was measured using infectivity 
assay as already described in section 3.2.2 in order to obtain thermal inactivation curve at 
80 °C.  
Second, HRV stock A (3.29 x 10
3
 TCID50/ml) was thermally treated as above. For PMA 
experiment, two identical HRV stock A samples were prepared at each time point; one 
sample was treated with 100 µM of PMA while the other was not. All samples were 
incubated for 5 min in the dark at room temperature and then exposed to light for 15 min. 
For RNase experiment, two HRV stock A samples were prepared at each time point; one 
sample was treated with 0.08 mg of RNase while the other was not. All samples were 
incubated for 30 min at 37 °C, and after which 80 U of RNase inhibitor was added only to 
the samples with RNase treatment. In each experiment, the non-pre-treated HRV stock A 
stored at 4 °C was used as a control. Finally, all samples were subjected to RNA extraction 
and analyzed with RT-qPCR assay. Each experiment was performed twice. 
Lastly, HRV stock B was prepared after the addition of RNase (0.08 mg) to aliquots of 140 
µl of HRV stock A and incubated at 37 °C for 30 min, after which 80 U of RNase inhibitor 
was added. A control was prepared by adding sterile H2O instead of RNase and RNase 
inhibitor. HRV stock B was also thermally treated as above. PMA and RNase experiments 
were performed as described above. In each experiment, the non-pre-treated HRV stock B 
stored at 4 °C was used as a control. Finally, all samples were subjected to RNA extraction 
and analyzed with RT-qPCR assay. Each experiment was performed twice. 
3.2.7 Viral RNA extraction  
 
RNA extraction was performed according to the manufactures’ instructions with QIAamp 
Viral RNA Mini Kit (QIAGEN, Hilden, Germany). Aliquots of 140 µl of each sample 
were applied for nucleic acid extraction, and nucleic acids were eluted in 60 µl of elution 
buffer and stored at – 20 °C. 
3.2.8 VP2 gene specific primers and probes 
 
The specific primers and probes targeting VP2 gene of HRV WA strain G1P[8] was used 
(Gutierrez-Aguirre and others 2008). The sequence of the primer pairs and probe was as 
follows: the forward primer (VP2-F2): 5’-CAGACACGGTTGAACCCATTAA-3, the 
reverse primer (VP2-R1): 5’-GTTGGCGTTTACAGTTCGTTCAT-3’ and the VP2 
Taqman probe: 5’-FAM-ATGCGCATRTTRTCAAAHGCAA-MGB-3’. The target gene 
sequence can be found with accession numbers X14942.1 in Nucleotide Database, in 
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National Center for Biotechnology Information (NCBI, Bethesda MD, USA). It generated 
amplification products of 84 bp. 
3.2.9 RT-qPCR assay 
 
One step RT-qPCR amplifications were performed in duplicate using Rotor-gene 3000 
thermal cycler (Corbett Life science, Sydney, Australia). Each reaction was performed in a 
20 µl reaction mixture containing 5 µl of template, 0.9 µM each forward and reserve 
primers (VP2-F2 and VP2-R1), 0.26 µM of VP2 Taqman probe, 10 µl of 1x QuantiTect 
Probe RT-PCR Master Mix (QIAGEN, Hilden, Germany), 0.2 µl of QuantiTect RT Mix 
(QIAGEN, Hilden, Germany), and 2.4 µl of RNase-Free water. The reaction conditions 
were as follows: reverse transcription of RNA for 60 min at 50 °C followed by PCR initial 
activation step for 10 min at 95 °C, and finally the 45 cycles of 2-step cycling step 
including; denaturation for 15 sec at 95 °C and combined annealing and extension for 60 
sec at 60 °C.   
The PCR titer of HRV stock A was measured using a standard curve. The standard curve 
was generated by amplifying 10-fold serial dilutions of original HRV stock from 10
-2
 to  
10
-8
 by RT-qPCR assay in duplicate. The quantification cycle (Cq) at which target gene 
was amplified at exponential phase was determined by fluorescence threshold of 0.03. The 
Cq obtained from each dilution was used to plot the standard curve in the way that the 
highest dilution (10
-7
) showing a positive results with Cq (< 40) was assigned a 
concentration of 10 RT-qPCR detectable virus units (PCR-units) and progressively 10-fold 
higher values to the lower dilutions, respectively. The equation of linear regression and the 
correlation coefficient (r
2
) values were then obtained for the standard curve, and from the 
slope of the regression curve, PCR amplification efficiency was calculated according to 
following equation:             ⁄    , where a value of 1 corresponds to 100 % 
efficiency. The PCR titer of unknown samples was determined by plotting the 
corresponding Cq value against the standard curve obtained as above. All unknown 
samples were analyzed with RT-qPCR assay in duplicates, and in every set of samples, two 
positive controls, one negative control for RNA extraction, one negative PCR control and 
one non-template control (NTC) were included. 
 
 
32 
 
3.2.10 Statistical analysis   
 
Student’s t test was used to evaluate the significance of difference among the mean 
numbers of virus titers between treated and non-treated samples, with a significance level 
of P < 0.05 (Microsoft Office Excel, Microsoft, Redmond, USA).  
3.3 Results 
3.3.1 Standard curve  
 
The standard curve of HRV RT-qPCR assay was generated (Figure 6). The last dilution  
10
-7 
showing positive Cq value (< 40) was assigned to the concentration of 10 RT-qPCR 
units which was the lowest level of detection per each reaction. As each reaction contained 
5 µl of template, the detection limit of RT-qPCR assay was estimated to be 2 PCR-units 
per 1 µl of template. The PCR titer of HRV stock A was determined as 1.0 x 10
6
 PCR-
units per 5 µl of template. The linear dynamic ranges of detection were from 10
1
 to 10
6
 
PCR-units. The linear regression curve was obtained using following equation:     
                . The correlation coefficient (r2) was 0.983 and the amplification 
efficiency was 0.69.  
 
Figure 6. Standard curve of HRV RT-qPCR assay. The Cq obtained from each dilution was used to plot a 
standard curve in the way that the highest diluton (10
-7
) with a Cq (< 40) was assigned a concentration of 10 
PCR-units per 5 µl, and progressively, 10-fold higher values to the lower dilutions 10
-6
, 10
-5
, 10
-4
, 10
-3
 and 
10
-2
 respectively. 
3.3.2 Validation of PMA treatment  
 
The effects of light exposure and different PMA concentrations (50 and 100 µM) on 
infectious HRV stock A were investigated (Table 5). The effect of light exposure alone on 
infectious HRV stock A was negligible. PMA treatment without light exposure to 
infectious HRV stock A had no effect on virus titer detected by RT-qPCR assay regardless 
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of the PMA concentrations. On the other hand, after PMA treatment upon light exposure, 
the virus titer of infectious HRV stock A was decreased by slightly more than 1 log10 PCR-
unit. The reduction level was slightly higher with PMA at a final concentration of 100 µM 
than at 50 µM. 
Table 5. The effects of light exposure and different PMA concentrations (50 and 100 µM) on infectious 
HRV stock A. 
 Level of HRV stock A (3.29 x 10
3
 TCID50/ml) 
 without light exposure with light exposure 
 
Quantification
1
 
Log10 (PCR-units) 
Reduction
2
 
Quantification
1
 
Log10 (PCR-units) 
Reduction
2
 
Infectious control 5,70 ± 0,05  5,66 ± 0,09  
Infectious + 50 µM PMA 5,72 ± 0,01 0,01 4,50 ± 0,33 1,16 
Infectious + 100 µM PMA 5,71 ± 0,08 0,00 4,37 ± 0,34 1,29 
1. HRV titers (PCR-units) were calculated by plotting the samples against the standard curve, and standard deviations 
were calculated among the biological replicates. 
2. Reduction in quantification between infectious viruses before and after PMA treatment. 
 
The effects of different PMA concentrations (50 and 100 µM) were preliminarily tested on 
thermally-treated HRV stock A at three different temperatures (37, 80, and 97 °C) for 30 
min (Table 6). PMA treatment to thermally-treated HRV stock A decreased the virus titers 
about 1 log10 PCR-unit regardless of temperature (data at 97 °C not shown). The reduction 
level was slightly higher with PMA at a final concentration of 100 µM than 50 µM. Even 
after PMA treatment (100 µM), the titer of thermally-treated HRV stock A at 80 °C for 30 
min (4.49 log10 PCR-units) was still as high as the titer of infectious HRV stock A (4.37 
log10 PCR-units) (Table 5).  
 
Table 6. The effects of PMA concentrations (50 and 100 µM) on thermally-treated HRV stock A. 
 Level of HRV stock A (3.29 x 10
3
 TCID 50/ml) 
 37 °C for 30 min 80 °C for 30 min 
 
Quantification
1
 
Log10 (PCR-units) 
Reduction
2
 
Quantification
1
 
Log10 (PCR-units) 
Reduction
2
 
Thermally-treated  
 control 
5,61   5,70  
Thermally-treated  
+ 50 µM PMA 
4,67 0,94 4,80 0,90 
Thermally-treated  
+ 100 µM PMA 
4,44 1,13 4,49 1,21 
1. HRV titers (PCR-units) were calculated by plotting the samples against the standard curve, and standard deviations 
were calculated among the biological replicates. 
2. Reduction in quantification between inactivated viruses before and after PMA treatment. 
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The binding of PMA (100 µM) to extracted viral RNA was investigated (Table 7). PMA 
treatment to non-purified viral RNA upon light exposure decreased virus titer by 4 log10 
PCR-units. After RNA purification with QiaQuick PCR purification kit, the reduction level 
was decreased by 3 log10 PCR-units. In addition, PMA treatment to non-purified viral RNA 
without light exposure decreased virus titer by 5.12 log10 PCR-units, while the virus titer 
rendered similar as the titer of control viral sample after the purification.  
Table 7. The binding of PMA on viral RNA with and without purification. 
 Level of HRV stock A (3.29 x 10
3
 TCID50/ml) 
 Without purification With purification 
 Quantification
1
 
Log10 (PCR-units) 
Reduction
2
 Quantification
1
 
Log10 (PCR-units) 
Reduction
2
 
Viral RNA control 5,50 ± 0,04  5,47 ± 0,00  
Viral RNA  
+ 100 µM PMA
3
 
1,42 ± 0,29 4,08 2,45 ±0,22 3,02 
Viral RNA 
+ 100 µM PMA
4
 
0,38 ± 0,54 5,12 5,36 ±0,05 0,11 
1. HRV titers (PCR-units) were calculated by plotting the samples against the standard curve, and standard deviations 
were calculated among the biological replicates. 
2. Reduction in quantification between viral RNA before and after PMA treatment. 
3. With light exposure and analyzed with RT-qPCR assay. 
4. Without light exposure and analyzed with RT-qPCR assay. 
 
3.3.3 Validation of RNase treatment  
 
The effects of different RNase doses (0.04 and 0.08 mg) on infectious HRV stock A were 
evaluated (Table 8). RNase treatment decreased virus titers slightly more than 1 log10 PCR-
unit. The reduction level was slightly higher with 0.08 mg of RNase than 0.04 mg. 
Table 8. The effects of two different doses (0.04 and 0.08 mg) of RNase on infectious HRV stock A. 
 Level of HRV stock A (3.29 x 10
3
 TCID50/ml) 
 Quantification
1
 
Log10 (PCR-units) 
Reduction
2
 
Infectious control 5,65 ± 0,14  
Infectious + 0,04 mg RNase 4,61 ± 0,37 1,04 
Infectious + 0,08 mg RNase 4,39 ± 0,62 1,26 
1. HRV titers (PCR-units) were calculated by plotting the samples against the standard curve, and standard deviations 
were calculated among the biological replicates. 
2. Reduction in quantification between infectious virus before and after RNase treatment. 
 
The effects of different RNase doses (0.04 and 0.08 mg) were preliminarily tested on 
thermally-treated HRV stock A at different temperature (37, 80, and 97 °C) for 30 min 
(Table 9). RNase treatment decreased the titer of virus incubated at 37 °C for 30 min about 
1 log10 PCR-unit. On the other hand, the titer of thermally-treated virus at 80 °C for 30 min 
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was decreased by 3 log10 PCR-units, and the similar reduction level was also observed for 
thermally-treated virus at 97 °C for 30 min (data not shown). The reduction levels of virus 
titer were similar for both RNase doses (0.04 and 0.08 mg) 
Table 9. The effects of two different doses (0.04 and 0.08 mg) of RNase on thermally-treated HRV stock A. 
 Level of HRV (3.29 x 10
3
 TCID50/ml) 
 37 °C for 30 min 80 °C for 30 min 
 
Quantification
1
 
Log10 (PCR-units) 
Reduction
2
 
Quantification
1
 
Log10 (PCR-units) 
Reduction
2
 
Thermally-treated  
 control 
5,64   5,56  
Thermally-treated  
+ 0,04 mg RNase 
4,59 1,05 2,60 2,95 
Thermally-treated 
+ 0,08 mg RNase 
4,51 1,13 2,62 2,94 
1. HRV titers (PCR-units) were calculated by plotting the samples against the standard curve, and standard deviations 
were calculated among the biological replicates. 
2. Reduction in quantification between inactivated viruses before and after PMA treatment. 
 
3.3.4 Thermal inactivation curve  
 
The infectivity of original HRV stock was measured by cell culture-based infectivity assay 
after heat treatment at 80 °C at different time points, and thermal inactivation curve was 
generated (Figure 7). The initial infectivity of HRV without any heat treatment was 3.29 x 
10
5
 TCID50/ml. After 1 min, the infectivity level of HRV was dramatically decreased to 
1.04 x 10 TCID50/ml. After 5 min, HRV was completely inactivated. The detection limit of 
infectivity assay was estimated to be 2.18 TCID50/ml. 
 
 
Figure 7. Thermal inactivation curve of original HRV stock at 80°C. x (horizontal) axis stands for different 
time points applied at 80 °C, and y (vertical) axis stands for the infectivity level of virus by log (TCID50/ml). 
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3.3.5 PMA treatment to monitor thermal inactivation of HRV stock A 
 
The potential of PMA treatment to distinguish infectious and thermally-treated HRV stock 
A was investigated (Figure 8). Using RT-qPCR assay, similar virus titers (black column in 
Figure 8) were observed for both infectious and thermally-treated HRV regardless of 
inactivation time. On the other hand, virus titers measured by RT-qPCR assay with PMA 
treatment (gray column in Figure 8) were significantly (P < 0.05) different from the titers 
measured by RT-qPCR assay alone. After PMA treatment, the titer of infectious HRV was 
decreased by 1.29 log10 PCR-units. The reduction levels were similar for thermally-treated 
HRV regardless of inactivation time (ranges from 1.04 to 1.24 log10 PCR-units).  
 
Figure 8. Quantification of infectious and thermally-treated HRV stock A (containing 3.29 x 10
3
 TCID50/ml) 
with and without PMA treatment; RT-qPCR without PMA treatment (black column) and RT-qPCR with 
PMA treatment (gray column). x (horizontal) axis stands for different time points (min) applied at 80 °C, and 
y (vertical) axis stands for virus titers (PCR-units) detected by RT-qPCR assay and calculated to log10 (PCR-
units). 
 
3.3.6 RNase treatment to monitor thermal inactivation of HRV stock A 
 
The potential of RNase treatment to discriminate infectious and thermally-treated HRV 
stock A was evaluated (Figure 9). The titers of both infectious and thermally-treated HRV 
measured by RT-qPCR assay with RNase treatment (gray column in Figure 9) were 
significantly (P < 0.05) different from the titers measured by RT-qPCR assay alone (black 
column in Figure 9). After RNase treatment, the titer of infectious HRV was decreased by 
0.81 log10 PCR-unit. The reduction level was similar after 1 min of heat treatment, whereas 
the reduction level was increased by 2.6 log10 PCR-units after 5 min and slightly more after 
10 min, and maximum decrease (2.9 log10 PCR-units) was obtained after 60 min of heat 
treatment.  
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Figure 9. Quantification of infectious and thermally-treated HRV stock A (containing 3.29 x 10
3
 TCID50/ml) 
with and without RNase treatment; RT-qPCR without RNase treatment (black column) and RT-qPCR with 
RNase treatment (gray column). x (horizontal) axis stands for different time points (min) applied at 80 °C, 
and y (vertical) axis stands for virus titers (PCR-units) detected by RT-qPCR assay and calculated to log10 
(PCR-units). 
 
3.3.7 Comparison of PMA and RNase treatment on HRV stock A 
 
The efficiencies of PMA and RNase treatments were compared for their potential to 
discriminate infectious and thermally-inactivated HRV for 60 min at 80 °C, which 
treatment completely destroyed viral infectivity according to the infectivity assay (Table 
10). PMA (100 µM) treatment of inactivated HRV stock A decreased the virus titer by 1 
log10 PCR-unit, whereas RNase (0.08 mg) treatment reduced the titer by 2.89 log10 PCR-
units. The higher reduction level of inactivated HRV for 60 min at 80 °C was observed by 
RNase treatment than PMA treatment. 
Table 10. Comparison of PMA and RNase treatment between infectious and inactivated HRV stock A at 
80 °C for 60 min. 
  PMA RNase 
 PMA or 
RNase 
Quantification 
a
 
Log10 (PCR-units) 
Reduction Quantification 
a
 
Log10 (PCR-units) 
Reduction 
Infectious HRV  - 5,68 ± 0,25  5,51 ± 0,12  
+ 4,39 ± 0,05 1,29
b
 4,70 ± 0,35 0,81
b
 
Inactivated HRV 
(60 min at 80 °C) 
 - 5,63 ± 0,28  5,52 ± 0,11  
+ 4,57 ± 0,21 1,07
c
 2.63 ± 0,33 2,89
c
 
a. HRV titers (PCR-units) were calculated by plotting the samples against the standard curve, and standard deviations 
were calculated among the biological replicates. 
b. Reduction in quantification between infectious virus before and after PMA or RNase treatment. 
c. Reduction in quantification between inactivated virus before and after PMA or RNase treatment. 
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3.3.8 PMA treatment to monitor thermal inactivation of HRV stock B 
 
The potential of PMA treatment to HRV stock B was also evaluated (Figure 10). First, 
using RT-qPCR assay alone, the titers of both infectious and thermally-treated HRV stock 
B (black column in Figure 10) were significantly (P < 0.05) different from the titers of 
those HRV stock A (black column in Figure 8). In comparison to the titer of infectious 
HRV stock A, the titer of infectious HRV stock B was decreased by 1 log10 PCR-unit. The 
titers of thermally-treated HRV stock B were gradually decreasing from 1 min to 10 min, 
and remained constant until 60 min of heat treatment. Moreover, the titers of both 
infectious and thermally-treated HRV stock B measured by RT-qPCR assay with PMA 
treatment (gray column in Figure 10) were significantly different (P < 0.05) from the titers 
of those HRV stock B measured by RT-qPCR assay alone (black column in Figure 10). 
After PMA treatment, the titer of HRV stock B without heat treatment reduced by 1.77 
log10 PCR-units, while the reduction level was not higher for thermally-treated HRV stock 
B; it gradually decreased from 1 min to 10 min, and it rendered similar (less than 1 log10 
PCR-unit) for the viral samples inactivated more than 10 min of heat treatment.  
 
Figure 10. Quantification of infectious and thermally-treated HRV stock B with and without PMA treatment; 
RT-qPCR without PMA treatment (black column) and RT-qPCR with PMA treatment (gray column). x 
(horizontal) axis stands for different time points (min) applied at 80 °C, and y (vertical) axis stands for virus 
titers (PCR-units) detected by RT-qPCR assay and calculated to log10 (PCR-units). 
 
3.3.9 RNase treatment to monitor thermal inactivation of HRV stock B 
 
The potential of RNase treatment to HRV stock B was also evaluated (Figure 11). The 
titers of both infectious and thermally-treated HRV stock B measured by RT-qPCR assay 
with RNase treatment (gray column in Figure 11) were not significantly (P > 0.05) 
different from the titers of those HRV stock B measured by RT-qPCR assay alone (black 
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column in Figure 11). In contrast to the previous result, the effect of RNase treatment to 
HRV stock B was negligible as it decreased the titers of both infectious and thermally-
treated HRV by less than 1 log10 PCR-unit. 
 
Figure 11. Quantification of infectious and thermally-treated HRV stock B with and without RNase 
treatment; RT-qPCR without RNase treatment (black column) and RT-qPCR with RNase treatment (gray 
column). x (horizontal) axis stands for different time points (min) applied at 80 °C, and y (vertical) axis 
stands for virus titers (PCR-units) detected by RT-qPCR assay and calculated to log10 (PCR-units). 
3.3.10 Comparison of PMA and RNase treatment on HRV stock B 
 
The efficiencies of these two treatments were also compared for their potential to 
discriminate infectious and thermally-inactivated HRV stock B for 60 min at 80 °C (Table 
11). PMA (100 µM) treatment reduced the titer of infectious HRV stock B by almost 2 
log10 PCR-units, whereas less than 1 log10 PCR-unit reduction was obtained for thermally-
inactivated HRV stock B. RNase (0.08 mg) treatment decreased the titers of both 
infectious and inactivated HRV stock B by less than 1 log10 PCR-unit. Both treatments 
decreased the titers of both infectious and inactivated virus by less than 1 log10 PCR-unit. 
Table 11. Comparison of PMA and RNase treatment between infectious and inactivated HRV stock B at 
80 °C for 60 min. 
  PMA RNase 
 PMA or 
RNase 
Quantification 
a
 
Log10 (PCR-units) 
Reduction Quantification 
a
 
Log10 (PCR-units) 
Reduction 
Infectious HRV  - 4,67 ± 0,13  4,74 ± 0,04  
+ 2.90 ± 0,03 1,77
b
 4,44 ± 0,24 0,30
b
 
Inactivated HRV 
(60 min at 80 °C) 
 - 2,66 ± 0,05  2,70 ± 0,16  
+ 1.87 ± 0.08 0,79
c
 2.06 ± 0.21 0,64
c
 
a. HRV titers (PCR-units) were calculated by plotting the samples against the standard curve, and standard deviations 
were calculated among the biological replicates. 
b. Reduction in quantification between infectious virus before and after PMA or RNase treatment. 
c. Reduction in quantification between inactivated virus before and after PMA or RNase treatment. 
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3.4 Discussion 
 
Despite the significance of rotavirus in public health, current methods for rotavirus 
detection are limited mainly due to the lack of information on viral infectivity which is 
critical to assess infectious risk to population (Gassilound and others 2003; Duizer and 
others 2004; Choi and Jian 2005; Rodriguez-Lazaro and others 2012). In order to establish 
a reliable and reproducible molecular method for rotavirus detection with information of 
viral infectivity, the potential of using RT-qPCR assay combined with PMA or RNase 
treatment to measure the infectivity of human rotavirus (HRV) was investigated.  
The validation of PMA and RNase treatments 
In order to assess the viral infectivity, several approaches have recently been developed on 
the basis of using PCR assays. First, one of the promising approaches is pre-treatment of 
virus sample with a viability dye such as ethidium monoazide (EMA) or propidium 
monoazide (PMA), prior to PCR-based assay (Fittipaldi and others 2011). Both EMA and 
PMA are DNA intercalating dyes that can possibly only penetrate to the damaged or 
compromised capsid of inactivated or non-infectious viruses, and covalently bind to viral 
RNA upon light exposure, and inhibit its amplification by PCR assay (Gensberger and 
Kostic 2013). On the other hand, the dyes possibly do not penetrate to intact capsid of 
infectious viruses, and thus those viral RNA of infectious viruses can successfully amplify 
by PCR assay (Fittipaldi and others 2012). Due to the lack of specificity of EMA treatment 
for intact cells and higher permeability of PMA than EMA to intact cells of bacteria, PMA 
treatment seems to be more promising. Some studies have evaluated the applicability of 
PMA treatment combined with PCR-based assays on enteric viruses; bacteriophage T4 
(Fittipaldi and others 2010), poliovirus (Parshionikar and others 2010), hepatitis A virus 
(Sanchez and others 2012), murine norovirus (Kim and others 2012) and recently human 
rotavirus (Coundray-Meunier and others 2013). Most studies claimed that PMA treatment 
combined with PCR-based assay would be a useful tool to assess the viral infectivity under 
defined condition, as the applicability of this assay was depending on virus species and 
inactivation methods applied. The generation of false-positive signals remains to be the 
greatest concern.  
In this study, the effects of PMA treatment on infectious and thermally-treated HRV stock 
A were preliminarily tested. First, the light exposure and PMA itself without light exposure 
had no effect on infectious virus. On the other hand, PMA treatment (50 and 100 µM) 
upon light exposure decreased the titer of infectious virus slightly more than 1 log10 unit 
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(reduction levels from 1.16 to 1.29 log10 units). The similar reduction levels (from 0.09 to 
1.21 log10 units) were observed when PMA was treated to thermally-treated viruses 
regardless of PMA concentrations and temperatures used for inactivation. These results 
were in disagreement with the ones from previous studies; the addition of PMA to 
infectious virus did not have strong effects on virus titer detected by PCR assays, whereas 
higher reduction level of virus titer were obtained when PMA was treated to inactivated 
viruses. For instance, Coundray-Meunier and others (2013) found that PMA treatment to 
infectious rotavirus decreased the virus titer ranging from 0.05 log10 to 0.63 log10 units 
depending on PMA concentration used (50, 75 and 100 µM), whereas they observed the 
maximum decrease (about 1.45 log10 units) for thermally-inactivated rotavirus (for 10 min 
at 80 °C) with PMA at a final concentration of 100 µM. Fittipaldi and others (2010) 
observed almost 7 log10 units reduction for thermally-inactivated bacteriophage T4 viruses 
(for 15 min at 110 °C) using PMA treatment (100 µM) whereas only 0.66 log10 unit 
reduction for infectious virus. In addition, Sanchez and others (2012) observed that PMA 
treatment to infectious hepatitis A virus reduced its titer less than 0.35 log10 unit, while 
more than 2.5 log10 unit reduction was obtained with thermally-inactivated viruses (for 5 
min at 99 °C). Thus, the validity of PMA treatment on our HRV stock A was doubtful due 
to similar reduction levels observed between infectious and inactivated viruses.  
Accordingly, it was hypothesized that PMA concentration chosen for this study may not be 
sufficient enough to bind to all of viral RNA in HRV stock A, so that the binding of PMA 
to viral RNA was tested. As PMA treatment of 100 µM to thermally-treated viruses 
yielded a slightly higher reduction level (0.03 log10 units) than 50 µM, PMA at a final 
concentration of 100 µM was chosen for this experiment. In contrast to our hypothesis, 4 
log10 units reduction was obtained with PMA treatment to the given amount of viral RNA 
(1.0 x 10
6
 PCR-units) upon light exposure. The reduction level of 3 log10 units was 
observed after RNA purification, implying the inhibitory effect of unbound PMA or excess 
PMA. The reduction levels in our study were even higher than the ones in the previous 
study of Coundray-Meunier and others (2013) where the reduction level of 2 log10 units 
was observed when 10
8
 genome copies of viral RNA were treated with PMA at 
concentration of 100 µM. Our result indicated that PMA at a final concentration at 100 µM 
was able to sufficiently bind to all of viral RNA. In addition, another minor finding in this 
experiment was that PMA (100 µM) had inhibitory effect on viral RNA without light 
exposure, as only 0.38 log10 PCR-unit was detectable which was below the detection limit 
of RT-qPCR assay. However, the inhibitory effect was efficiently removed by RNA 
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purification step. This finding corresponded to the study where PMA concentrations 
ranging from 50 to 200 µM totally inhibited RT-qPCR amplification of viral RNA 
(Coundray-Meunier and others 2013). In consequence, PMA at final concentration of 100 
µM was chosen for further studies in order to investigate its potential to assess the viral 
infectivity in comparison to RT-qPCR assay alone and cell culture-based infectivity assay. 
Next, another promising approach to assess the viral infectivity is enzymatic treatment 
combined with RT-qPCR assay. This approach was first introduced by Nuanualsuwan and 
Cliver (2002). They used the pre-treatment of virus samples with Proteinase K and RNase 
prior to RT-PCR assays. Based on the fact that the viral infectivity requires the functional 
integrity of viral capsid and viral genome, they added Proteinase K to degrade capsid 
proteins damaged by inactivation, and then RNase to reach viral RNAs released from the 
degraded viral capsids. In their study, hepatitis A virus, poliovirus, and feline calicivirus 
were thermally inactivated at 72 °C, and both enzymes were treated prior to RT-PCR. 
Enzymes treated viruses gave negative PCR results, while positive result was obtained 
with PCR without any enzymes digestion. Later, some studies have investigated the 
applicability of enzymatic treatment combined with PCR-based assays on enteric viruses; 
bacteriophage MS2 (Pecson and others 2009), hepatitis A virus (Sanchez and others 2012), 
human norovirus (Rönnqvist and others 2014), and murine norovirus (Baert and others 
2008; Rönnqvist and others 2014). Most studies suggested that this approach could be 
useful to track infectivity at some degree, while the applicability of this assay may be 
limited due to the generation of false-positive results.   
In this study, the effects of RNase treatment on infectious and thermally-treated HRV stock 
A were preliminarily tested. Although the use of both Proteinase and RNase had 
synergistic effect on signal reduction (Baert and others 2008; Rönnqvist and others 2013), 
RNase treatment alone was used in this study. This was because the purpose of using 
Proteinase in previous studies was mainly to attack the viral capsids, so that high 
concentration of Proteinase K may also affect intact capsids. Thus, the absence of 
Proteinase K was expected to be negligible. RNase treatment (0.04 and 0.08 mg) decreased 
the titer of infectious virus by slightly more than 1 log10 unit (reduction levels from 1.04 to 
1.26 log10 units). This reduction level was slightly higher than previous studies; Baert and 
others (2008) found that the use of RNase treatment alone did not have strong impact on 
the number of genome copies of the unheated murine noroviruses, and Rönnqvist and 
others (2013) observed that the loss of RNA was less than one log unit after the enzymatic 
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treatment of infectious viruses. The reason for obtaining higher reduction level in this 
study may imply the presence of external viral RNA in our virus stock.  
Moreover, the similar reduction level (about 1 log10 unit reduction) was observed for the 
viruses incubated at 37 °C for 30 min. On the other hand, maximum decrease (3 log10 unit 
reduction) was obtained for thermally-treated virus at 80 °C and 97 °C for 30 min. Similar 
results were found in previous studies; Nuanualsuwan and Cliver (2003) found that capsid 
of those inactivated viruses at 37 °C were still detectable after RNase treatment, while that 
of those inactivated at 72 °C was no longer detectable. Since the thermal inactivation at 72 
°C significantly attacks the viral capsids, the capsids became susceptible to both enzymes 
and can no longer protect viral RNA. Moreover, Pecson and others (2009) observed that 
the elimination of false-positive signals using enzymatic treatment differed between 
inactivating treatments. Accordingly, this corresponding result may demonstrate the 
limitation of using this method in that capsid integrity as criterion for viral infectivity may 
be limited, while at the same time, it indicated that RNase treatment may be able to attack 
RNA in case of thermal inactivation at 80 °C. 
Even though the similar reduction level was observed for both RNase doses, 0.08 mg of 
RNase was chosen for further studies to ensure sufficient amount of RNase to degrade the 
external RNA released from damaged virus particles. This was based on the previous study 
by Rönnqvist and others (2013) where they observed that too high concentration of 
proteinase reduced the number of presumably viable viruses whereas too low concentration 
of either enzyme was not enough to digest the damaged virus particles. They suggested the 
importance of enzyme concentration and balance between proteinase and RNase enzyme. 
PMA and RNase treatments to monitor thermal inactivation of HRV stock A  
From preliminary test, heat treatment at 80 °C as one of disinfection methods was selected 
as it was expected to cause the damage on viral capsid, and different time points (0, 1, 5, 
10, 20, 30, and 60 min) were employed to investigate the potential of PMA and RNase 
treatment to discriminate between infectious and thermally-treated rotavirus. First, thermal 
inactivation curve of original HRV stock was generated using the cell culture-based 
infectivity assay. After 1 min of heat exposure at 80 °C, the virus titer was dramatically 
decreased from 3, 29 x 10
5
 TCID50/ml to 1, 04 x 10 TCID50/ml (4 log10 reduction). After 5 
min, infectivity was completely destroyed (> 5 log10 reduction). It demonstrated that the 
heat exposure at 80 °C for 5 min was sufficient to inactivate the rotavirus. In previous 
study, Ojeh and others (1995) found that autoclaving for 15 min at 121°C completely 
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destroyed the infectivity of rotavirus as well as amplifiable viral RNA by PCR assay. 
Moreover, Estes and others (1979) found that heating at 50 °C for 30 min inactivates 99% 
of the rotavirus infectivity. Mahony and others (2000) observed more than 7 log10 
reduction of rotavirus infectivity after the heat exposure at 60 °C 10 min.  
Next, the RT-qPCR assay with and without pre-treatments were applied to measure the 
titers of HRV stock A before and after heat treatment. Due to the higher sensitivity of RT-
qPCR assay than cell culture-based infectivity assay, HRV stock A was prepared by 
diluting to 10
-2
 of original HRV stock. Using RT-qPCR assay without any pre-treatments, 
the titer of infectious virus was about 5.5 log10 units, while the titer of thermally-treated 
virus remained constant even after heat treatment for 60 min at 80 °C. Although the results 
between cell culture (original HRV stock) and RT-qPCR assay (HRV stock A) were not 
equivalently comparable in this study due to different concentrations of HRV stocks, the 
discrepancy of results between cell culture and RT-qPCR assays demonstrated that RT-
qPCR assay without any pretreatment overestimated the infectivity of thermally-treated 
viruses. Similar result was observed in previous study by Baert and others (2008) where 
found that after heat exposure for 1 hour at 80 °C, more than 6 log10 genomic copies of 
murine norovirus was still detected by qPCR assay whereas more than 6 log10 unit 
reduction was observed using plaque assay only after 150 s at 80 °C. This result can be 
partially explained by the mechanism of heat inactivation. Volkin and others (1997) 
suggested that the mechanism of thermal inactivation above 65 °C might cause large 
irreversible structural change due to extensive protein unfolding. Nuanualsuwan and Cliver 
(2003) observed that heat treatment at 72 °C caused the conformational change in viral 
protein of human picornavirus and feline calicivirus, and enormously diminished the 
functions of capsid. They suggested that the target of thermal inactivation seemed to be 
viral capsid although it was temperature-dependent. In addition, Gassillound and others 
(2003) found a great difference in heat resistance between infectious viruses and viral 
genomes in mineral water. Higher temperature could modify the viral protein capsid, 
leading to inactivation while it had little effect on the viral genome, and the infectious 
particles were degraded more rapidly than viral genomes. Baert and others (2008) also 
claimed that heat inactivation seemed to have a much stronger detrimental effect on viral 
infectivity than on the integrity of viral genome. 
Moreover, several studies found the inconsistency between the number of infectious virus 
and the number of viral genome detected by PCR assays, leading to the overestimation of 
viral infectivity and possible viral risk (Gassilloud and others 2003; Duizer and others 
45 
 
2004; Choi and Jian 2005; Bosch and others 2008; Yeh and others 2009; Rodriguez-Lazaro 
and others 2012). These studies argued a need of interpretation of positive PCR results 
with caution, and claimed that detection of viral genomes may be necessary but not 
sufficient for assessment of the infectious risk for human population. 
Using RT-qPCR assay with PMA treatment, the titers of thermally-treated viruses (ranges 
from 4.52 to 4.67 log10 units) were similar as the titer of infectious viruses (4.39 log10 units) 
regardless of inactivation time. Although PMA treatment decreased the titers of both 
infectious and thermally-treated viruses by 1 log10 units compared to one without any pre-
treatment, the results were in disagreement with the one from cell culture assay. It may 
imply that PMA (100 µM) did not efficiently bind to inactivated viral particles after heat 
treatment, although the concentration of 100 µM seemed enough to bind the viral RNA in 
the preliminary test.  
In previous studies, the applicability of PMA treatment to assess the viral infectivity was 
shown to be depending on inactivation methods as well as virus species. Fittipaldi and 
others (2010) found that PMA could clearly differentiate non-infectious bacteriophage T4 
viruses from infectious viruses in case of extreme damage to viral capsid such as 110 °C of 
heat treatment but not in case of moderate heating (85 °C). They claimed that disinfection 
methods which did not directly damage viral capsid might lead to loss of infectivity, but 
render its capsid uncompromised, and therefore PMA failed to reach viral RNA. Likewise, 
Parshionikar and others (2010) found PMA treatment did discriminate non-infectious 
viruses when hypochlorite treatment, heat treatment at 37 °C and 72 °C were applied, but 
not for heat treatment at 19 °C. They highlighted that PMA can be used to assess the 
infectivity level under the conditions defined. Moreover, Coundray-Meunier and others 
(2013) found that the quantity of rotavirus remained constant in heat treatment at 37 °C, 
although the genome titers of rotavirus following heat treatment at 68 °C to 80 °C became 
similar to infectious titers when PMA treatment was used. In addition, Kim and others 
(2012) observed that PMA treatment could distinguish between infectious and thermally-
inactivated bacteriophage MS2, but not with murine norovirus. They claimed that the 
reason for difference in results may be due to difference in the size and secondary structure 
of nucleic acid of target virus, since the secondary structure of the nucleic acid can affect 
the binding affinity of PMA (Parshionikar and others 2010). 
However, in our case, PMA treatment showed similar levels of reduction (ranges from 1.04 
to 1.29 log10 PCR-units) for both infectious and thermally-treated viruses regardless of 
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temperatures and inactivation time used. Coundray-Meunier and others (2013) proved the 
potential of using PMA treatment to discriminate between infectious and thermally-
inactivated human rotaviruses at 80 °C, indicating that thermal inactivation at 80 °C was 
supposed to damage the capsids of human rotaviruses. Accordingly, the content of virus 
stock was thought not to be optimal for this study. Although virus stock was newly 
produced for this study, our rotavirus strain had been stored for more than 20 years. In 
consequence, one reason may be that several freezing-thawing during experiments might 
have easily caused the damage on viral capsid of our stock and had led to release viral 
RNA. In addition, it might have been that the presence of dead cells (MA-104 cells) which 
were also collected during production of our virus stock might have disrupted the binding 
of PMA on our virus stock. Some studies with bacteria have suggested that the presence of 
high number of dead cells seems to influence the false-positive results of PMA treatment 
(Wang and others 2009; Fittipaldi and others 2012). Although the reason for influence of 
dead cells is not currently clear, it may be that high numbers of dead cells might take up 
the dye resulting in the lower concentration of available dyes, and it is likely that the 
effectiveness of PMA may be reduced by increasing cell number (Varma and others 2009; 
Fittipaldi and others 2012).  
On the other hand, the results of using RT-qPCR assay with RNase treatment were 
different from the one with PMA treatment. The titer of heat-treated viruses for 1 min 
(4.69 log10 units) was similar as the titer of infectious virus (4.70 log10 units) after RNase 
treatment. Then, the titer of thermally-treated viruses for 5 min was decreased to 2.94 log10 
units, and the titer of 2.63 log10 units was observed for thermally-treated virus for 60 min 
(maximum decrease of 2.9 log10 units). Although the virus titers were gradually decreasing 
as longer inactivation time applied, this result was not completely in agreement with the 
one of cell culture assay. While the infectivity of virus after 1 min of heat treatment was 
reduced about 4 log10 TCID50 units in cell culture assay, the titer rendered similar with 
RNase treatment. It indicated that RNase treatment was not able to degrade the viral RNA 
in this condition. In consequence, it was hypothesized that 1 min of heat treatment might 
not be sufficient enough to damage the viral capsid and sufficiently expose RNA, although 
this condition caused the loss of viral infectivity to some extent. Although it never 
completely eliminated false-positive results of thermally-treated viruses even after 60 min 
of heat treatment, RNase treatment did decrease false-positive results of thermally-treated 
viruses to some extent, and reduction level was correlated to some degree to viral 
inactivation observed in cell culture assay. 
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Similar results were found in previous studies. Baert and others (2008) observed the 
reduction of heat-treated norovirus titer using enzymatic treatment, but high number of 
genome copies (more than 6 log10 units) was still detected even after enzyme treatment in 
the absence of infectious virus. Pecson and others (2009) also found that enzymatic 
treatment reduced the inactivated bacteriophage MS2 titer (more than 5 log10 units) but did 
not completely eliminate the false-positive signals. They considered this phenomenon as 
plateau effect, and they suggested that this incomplete degradation (plateau effect) may be 
related to both the secondary structure of genome and its association with the capsid, 
which may result in less RNA degradation due to the decreased access between the RNase 
and the genome. The plateau effect was also observed by Rönnqvist and others (2013). 
They found that enzymatic treatment reduced false-positive signals of damaged norovirus 
particles but it did not reach a level at which all inactivated virus particles would have been 
enzymatically digested. Thus, in accordance with the previous findings, the result in this 
study indicated that RNase could degrade the inactivated viral particles to some extent, 
although it could not completely exclude the inactivated viruses.   
So far, the RNase treatment seemed to be more effective than PMA treatment to 
discriminate the infectious and thermally-inactivated HRV stock A in defined condition. 
This was because thermally-inactivated HRV titer (for 60 min at 80 °C) was decreased by 
almost 3 log10 PCR-units with RNase treatment, and only 1 log10 PCR-units with PMA 
treatment. In case of Hepatitis A viruses, Sanchez and others (2012) found that PMA 
treatment was more effective than RNase treatment for differentiating infectious and 
thermally-inactivated hepatitis A viruses (for 5 min at 99 °C), as the virus titer reduced by 
more than 2.4 log10 units with PMA treatment whereas only 0.55 log10 units with RNase 
treatment. These finding may suggest that the applicability of both pre-treatments may 
depend on virus species.  
PMA and RNase treatments to monitor thermal inactivation of HRV stock B 
Yet, in order to confirm the effects of PMA and RNase treatments, further studies were 
necessary. This was mainly because the result of using RT-qPCR with PMA treatment 
raised the question whether our HRV stock was optimal for this study. In consequence, 
HRV stock B was prepared by treating RNase to the HRV stock A in order to remove the 
possible external RNA or dead cells. The RT-qPCR assay with and without pre-treatments 
were applied to measure the titers of HRV stock B before and after heat treatment. Using 
RT-qPCR assay without any pre-treatment, the titer of non-heat treated HRV stock B (4.67 
log10 units) was decreased about 1 log10 unit compared to the titer of non-heat treated HRV 
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stock A (5.65 log10 units). It implied the presence of external RNA outside intact capsid in 
the original virus stock as expected, and thus only complete viral particles which ideally 
contained intact capsid protecting viral genome (also called virion), were expected to 
remain in the HRV stock B. Due to the limitation of PCR assays previously described, it 
was assumed that the titers of HRV stock B with or without thermal inactivation would be 
similar using RT-qPCR assay without any pre-treatment. However, the titer of HRV stock 
B was gradually decreased from 1 min to 10 min of heat treatment, and remained constant 
after 10 min. This result can be explained by the co-occurrences of two possible 
hypotheses. First, although RNase was added on the purpose of removing the free external 
RNA, it was possible that the viral capsids became more vulnerable after RNase treatment 
with subsequent heat treatment, and in consequence the viral genome might have been 
released. At the same time, it might be that RNase inhibitor did not properly inhibit the 
activity of the RNase so that they were still able to bind the released viral genome during 
heat treatment, although enzyme was supposed to be inactivated after few minutes in 80 
°C. These hypotheses could be partially supported by a previous study. Gassillound and 
others (2003) suggested the slight decrease of viral genome quantities using RT-PCR assay 
alone after 140 days at 35 °C could have been due to the possible presence of RNase in 
which might have originated from the environmental or stool samples where virus stock 
was isolated, and the protection of capsid might have been partially disappeared with time 
at 35 °C, and in consequence RNase were able to digest viral RNA as soon as it became 
available outside the capsid. Thus, if these hypotheses above would have been correct, RT-
qPCR assay alone might have been discriminating between the infectious and thermally-
treated viruses to some extent, and would lead to difficulties in interpreting the true effect 
of PMA and RNase treatment in further studies.  
Using RT-qPCR with PMA treatment, the titer of HRV stock B without heat treatment was 
reduced by 1.77 log10 units after PMA treatment only. If these hypotheses above would 
have been accepted, PMA might have also excluded RNA from more vulnerable capsids of 
the infectious virus synergistically with the remained activity of RNase. Otherwise, it could 
have been that HRV stock B became non-infectious after RNase treatment, although it 
could not be confirmed as the infectivity titer of HRV stock B was not measured. On the 
other hand, the reduction levels of heat-treated HRV stock B (range from 0.52 to 1.62 log10 
units) were lower than those of non-heat treated (1.77 log10 units): the titer of heat-treated 
HRV stock B was gradually decreased from 1 to 10 min, and rendered similar (less than 1 
log10 unit) after 10 min of heat treatment. It might have been that PMA could not yield any 
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higher reduction level after longer time of heat treatment, as it was hypothesized that RT-
qPCR assay alone would have been already discriminating between the infectious and 
thermally-treated viruses to some extent.  
In contrast to the previous result of RT-qPCR assay with RNase treatment on HRV stock 
A, the effect of RNase treatment on HRV stock B was negligible. RT-qPCR assay with 
RNase treatment decreased the virus titers by less than 1 log10 unit for both HRV stocks B 
with and without heat treatment. The results of statistical analysis showed that the titers of 
HRV stock B measured by RT-qPCR assay with or without RNase treatment were 
significantly correlated. Although RNase treatment was applied twice before and after heat 
treatment in HRV stock B, it was likely that RNase treatment had the plateau effect due to 
the decreased access between the RNase and the genome as discussed before. 
Nevertheless, due to the lack of information on infectivity assay of HRV stock B, the true 
effect of PMA and RNase treatment to assess the viral infectivity is hard to compare in this 
condition.  
Overall evaluation of PMA and RNase treatments to human rotavirus 
All in all, PMA treatment seemed to bind rotavirus RNA to some extent by decreasing the 
false-positive results, although the high numbers of false-positive signals from thermally-
inactivated viruses were still detected even with PMA treatment. One of the main reasons 
for false-positive results in this study might be the shortness of the target gene region (84 
bp) amplified. In previous studies, Coundray-Meunier and others (2013) observed that the 
reduction level of virus titer was different depending on the RT-qPCR assays where 
different lengths of target gene were amplified. Moreover, Fittipaldi and others (2012) 
suggested that the amplification of longer target gene sequence correlates with a higher 
probability of discriminating between damaged and non-damaged gene, resulting in a 
stronger suppression of signals from dead cells.  
Indeed, the generation of false-positive signals due to incomplete signal suppression has 
been considered as the greatest concern using this assay, and in consequence, the need of 
optimizing the PMA treatment has been suggested for a successful application (Fittipaldi 
and others 2010). Fittipaldi and others (2012) claimed the several important factors to 
optimize this method; dye concentration, the incubation condition, the light source, the 
presence of high number of dead cells, the salt concentration or pH of the reaction mix, the 
length of target gene, and the sequence of the target gene etc. In this study, although RNase 
treatment was performed to remove the presence of external RNA or dead cells in our virus 
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stock, this treatment was still unsuccessful to obtain the optimal virus stock.  Thus, further 
studies may be necessary to focus on optimizing the assays such as using different primers, 
and producing the optimal virus stock in order to extensively evaluate the potential of 
PMA treatment to assess the infectivity of rotavirus. In addition, studies on the functional 
changes of rotavirus capsid and genome upon thermal inactivation at 80 °C would be 
helpful in understanding the effect of PMA on rotavirus.  
To our knowledge, this is the first study where RNase treatment was employed to assess 
the infectivity of human rotavirus. Although RNase treatment seemed to discriminate 
between infectious and thermally-treated HRV stock A in the early stage of the 
experiments, the results using HRV stock B gave conflicting findings. Thus it was not 
possible to confirm its effects on HRV. Nevertheless, RNase treatment seemed to degrade 
rotavirus RNA to some extent by eliminating the false-positive results of thermally-
inactivated rotaviruses, although the discrepancy between infectivity assays and enzymatic 
treatment with PCR assays was observed. Pecson and others (2009) claimed that the main 
advantage of using this assays is that it caused a significant decrease of false-positive 
signals and never contributed an additional false-positive signals, so that this assay would 
be a valuable tool regarding viral infectivity as the degree of reduction responded to 
inactivation in manner proportional to cell culture-based assays. In addition, they 
suggested that the relationship of inactivation curve between the cell culture and enzymatic 
treatment with PCR assays would need to be established for each virus and inactivating 
treatment, for the practical application of this assay.  
In order to confirm the applicability of RNase treatment to human rotavirus, further studies 
are necessary to produce the optimal virus stock and inactivation curve for that virus stock. 
The moderate heating (for 1 min for 80 °C) was not enough to cause the damage on viral 
capsids. Therefore, attempt to use proteinase prior to RNase treatment as most of other 
studies would be necessary. Moreover, it would be worth trying to investigate the potential 
of this assay to discriminate between infectious and inactivated rotavirus after other 
inactivation methods such as hypochlorite or ultraviolet light that are commonly used in 
disinfection treatments for drinking water. 
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4 CONCLUSION 
 
The purpose of the present study was to develop a robust molecular method for rotavirus 
detection with information of viral infectivity, and which may also contribute to the 
development of molecular methods for correct estimation of infectivity of non-cultivable 
health-significant viruses. First, the significance of rotavirus in public health and the need 
of reliable molecular methods for virus detection and promising methods were reviewed. 
Second, the potential of using PCR-based molecular assay combined with dye or 
enzymatic treatments to assess the infectivity of human rotavirus were evaluated. 
In summary, this study demonstrates that heat exposure at 80 °C for 5 min was sufficient to 
inactivate human rotavirus based on the infectivity assay, and shows that RT-qPCR assay 
did not distinguish between infectious and inactivated viral genomes, resulting in the 
overestimation of viral infectivity. Moreover, this study shows that RT-qPCR assay 
combined with PMA and RNase pre-treatment eliminated the false-positive results of RT-q 
PCR assay to some extent in defined conditions. However, this study still finds 
discrepancy between the infectivity assay and RT-qPCR assays even with PMA or RNase 
treatment. The current investigation was limited by the use of possibly non-optimal HRV 
stock.  
Thus, in order to confirm the potential of using PCR-based assay combined with PMA or 
RNase treatment to measure the infectivity of human rotavirus, further studies on 
optimization of PMA and RNase treatment as well as production of the optimal HRV stock 
would be necessary. Further studies on the functional changes of capsid and genomes of 
HRV by thermal inactivation would help to evaluate the effects of PMA and RNase 
treatments on thermally treated human rotavirus. Nevertheless, this study confirms the 
previous findings and contributes additional evidence that suggests the potential of using 
these assays to assess the infectivity of non-cultivable viruses in defined condition.  
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